

**ALL INDIA INSTITUTE OF MEDICAL SCIENCES,
ANSARI NAGAR, NEW DELHI-110029, INDIA
1ST FLOOR, STORE SECTION (HOSPITAL),
NEAR BLOOD BANK (Main)**

TENDER ENQUIRY DOCUMENT



Advertised Tender Enquiry No. : 29/H/Drugs/2025-26

Rate Contract items : Purchase of Drugs/Medicines/I.V. Fluids

Period of Rate Contract : 02 Years Rate Contract Basis

SECTION-I



ALL INDIA INSTITUTE OF MEDICAL SCIENCES
ANSARI NAGAR, NEW DELHI-110 029
NOTICE INVITING TENDERS (NIT)

Advertised Tender Enquiry No. : **29/H/Drugs/2025-26**

On behalf of Director, AIIMS, Ansari Nagar, New Delhi-110 029, online bids are invited in two bid system (Techno-Commercial Bid and Financial Bid) from eligible and qualified firms/manufacturer for supply of following Goods for conclusion of Rate Contract for a period of 02 Years: -

S. No.	Brief Description of Goods	Amount of Bid Security/EMD (INR)
1.	Purchase of Drugs/Medicines/I.V. Fluids on 02 years rate contract basis	Rs.50,000/-

CRITICAL DATE SHEET

Published Date & Time	10.10.2025 at 04:00 PM
Bid Document Download/Sale Start Date	10.10.2025 at 04:00 PM
Bid Submission Start Date & Time	20.10.2025 at 04:00 PM
Bid Submission End Date & Time	31.10.2025 at 04:00 PM
Bid Opening Date & Time	01.11.2025 at 04:00 PM

Instructions:

1. Bids shall be submitted online only at CPPP website:
<https://eprocure.gov.in/eprocure/app>.
2. The Bidder shall download the Tender Enquiry Document directly from the websites <https://eprocure.gov.in/eprocure/app> and shall not tamper/modify it including downloaded Price Bid template in any manner. In case if the same is found to be tempered/modified in any manner, Tender/Bid will be summarily rejected and EMD would be forfeited.
3. The complete bidding process is online. Bidders should be possession of valid Digital Signature Certificate (DSC) of class III for online submission of bids. Prior to bidding DSC need to be registered on the website mentioned above.
4. Bidders are advised to follow the instructions provided in the “Instructions for Online Bid Submission” in Para No. 11 of GIB of Tender Enquiry Document.
5. Bidders are advised to visit this website regularly to keep them updated, for any changes / modifications in the Tender Enquiry Document.
6. Intending bidder are advised to visit CPPP website <https://eprocure.gov.in/eprocure/app> regularly till closing date of submission of bid, for any corrigendum.
7. The documents to be submitted in their bid may be scanned with 100 dpi with black and white option which helps in fast uploading.
8. The EMD / Bid Security of **Rs. 50000/-** shall be deposited through Bank Guarantee / Demand Draft / FDR drawn in favor of the AIIMS MAIN GRANT. The original Earnest Money / Bid Security must be submitted to *Stores Officer (Hospital), Hospital Stores, 1st Floor, M.S. Office, Near Blood Bank, AIIMS, New Delhi-110 029* till “Bid Submission End Date & Time” as mentioned in “Critical Date Sheet” failing which the bid shall be summarily rejected.

SECTION - II
GENERAL INSTRUCTIONS TO BIDDERS (GIB)

A. PREAMBLE

1. Definitions and Abbreviations

1.1 The following definitions and abbreviations, which have been used in these documents shall have the meanings as indicated below:

1.2. Definitions:

- i) "Purchaser" means the organization i.e. AIIMS/Center/Hospital/Department/Sections purchasing goods as incorporated in the Tender Enquiry Document.
- ii) "Bid" means Quotation / Tender received from a Firm / Tenderer / Bidder.
- iii) "Bidder" means Tenderer/ the Individual or Firm submitting Bids / Quotation / Tender
- iv) "Supplier" means the individual or the firm supplying the goods as incorporated in the Rate Contract/Purchase Order.
- v) "Goods" means all articles, material, commodity, livestock, furniture, fixtures, raw material, spares, instruments, machinery, equipment, vehicles, medicines, assemblies, sub-assemblies, accessories, intangible products like software, technology transfer, licenses, patents or other intellectual properties purchased or otherwise acquired for the use of Government but excludes books, publications, periodicals, etc. for a library. The term 'goods' also includes works and services which are incidental or consequential to the supply of such goods, such as, transportation, insurance, installation, commissioning, training and maintenance.
- vi) "Services" means services allied and incidental to the supply of goods, such as transportation, installation, commissioning, provision of technical assistance, training, after sales service, maintenance service and other such obligations of the supplier covered under the Rate Contract.
- vii) "Bid Security" (BS) means Earnest Money Deposit / monetary or financial guarantee to be furnished by a bidder along with its tender.
- viii) "Contract" means Rate Contract/Purchase Order which means the written agreement entered into between the purchaser and the supplier, together with all the documents mentioned therein and including all attachments, annexure etc. therein.
- ix) "Performance Security" means monetary or financial guarantee to be furnished by the successful bidder for due performance of the Rate Contract/Purchase Order placed on it. Performance Security is also known as Security Deposit.
- x) "Consignee" means the Center/Hospital/Department/Sections /person to whom the goods are required to be delivered as specified in the Purchase Order.
- xi) "Specification" also called Technical Specifications means the document/standard that prescribes the requirement with which goods has to conform.
- xii) "Inspection" means activities such as measuring, examining, testing, gauging one or more characteristics of the product and comparing the same with the specified requirement mentioned in the Rate Contract/Purchase Order to determine conformity.
- xiii) "Day" means calendar day.

1.3. Abbreviations:

- i) "ATE" means Advertised Tender Enquiry
- ii) "NIT" means Notice Inviting Tenders.
- iii) "GIB" means General Instructions to Bidders
- iv) "SIB" means Special Instructions to Bidders
- v) "GCC" means General Conditions of Contract
- vi) "SCC" means Special Conditions of Contract
- vii) "DP" means Delivery Period
- viii) "BG" means Bank Guarantee
- ix) "GST" means Goods & Service Tax
- x) "RC" means Rate Contract

2. Introduction

- 2.1 The AIIMS is the premier multi-disciplinary super specialty health sciences institution of India. It was established in 1956 by an Act of Parliament. AIIMS has a trinity of mission, which is medical education, research and patient care. It has around 2400 indoor beds with over 2.5 lakhs admissions per annum and an annual out-patient attendance of around 40,00,000 patients. The All India Institute of Medical Sciences (AIIMS) is catering Drugs/Medicines/I.V. Fluids to all E.H.S. patients, all essential drugs and I.V. Fluids to indoor patients. The list of Drugs/Medicines/I.V. Fluids required by AIIMS, is enclosed herewith for your information/reference (enclosed at Annexure-A).
- 2.2 This tender is for the purpose for executing rate-contract for supply of medicines at whole of the AIIMS (including all centres viz. CT & NS centre, Dr. BRA IRCH, NDDTC Ghaziabad, Rural Health Centre Ballabgarh, JPNATC, DR. RPC and Main Hospital).
- 2.3 The Purchaser has issued these Tender Documents for purchase of goods as mentioned in Section – VI – "Schedule of Requirements", which also indicates, *interalia*, the required delivery schedule, terms and place of delivery.
- 2.4 This section (Section II - "General Instructions to Bidders") provides the relevant information as well as instructions to assist the prospective bidders in preparation and submission of bids. It also includes the mode and procedure to be adopted by the bidder for receipt and opening as well as scrutiny and evaluation of bids and subsequent placement of Rate Contract/Purchase Order.
- 2.5 The bidder shall also read the Special Instructions to Bidders (SIB) related to this purchase, as contained in Section III of these documents and follow the same accordingly. Whenever there is a conflict between the GIB and the SIB, the provisions contained in the SIB shall prevail over those in the GIB.
- 2.6 Before formulating the bid and submitting the same to the purchaser, the bidder should read and examine all the terms, conditions, instructions, etc. contained in the Tender Document. Failure to provide and/or comply with the required information, instructions etc. incorporated in these Tender Documents may result in rejection of its Bid.
- 2.7 The rates quoted, approved and accepted by the Director, AIIMS shall be valid for **two years** from the date of signing of the agreement deed (**extendable up-to one year on mutual agreement, if required**).
- 2.8 **The tenders are to be submitted by the manufacturers/sole importer only. Tenders quoted by suppliers on behalf of manufacturers will not be entertained even if they are authorized by the manufacturers.** However, manufacturers can give authority letter to the supplier / distributor / stockiest for the purpose of making supplies, raising bills, collecting payment etc. only after selection in the tender. **In such cases, the manufacturer has to accept**

responsibility for any lapse on the part of the distributor/supplier and an undertaking to this effect from the manufacturer will have to be submitted. Failure to submit such an undertaking will lead to rejection of authorization and manufacturer will have to supply drugs directly. This authorization should be valid for the entire duration of the contract. **No change in the authorized supplier/distributor will be allowed during the rate contract period. Different distributors of a manufacturer for different Centers/Hospital will not be allowed. Sub authorization further to any other agent for delivery of the goods or for raising bills/collecting payment etc. will not be accepted.**

3. Availability of Funds

- 3.1 Expenditure to be incurred for the proposed purchase will be met from the funds available with the purchaser/consignee.

4. Language of Bid

- 4.1 The bid submitted by the bidder and all subsequent correspondence and documents relating to the bid exchanged between the bidder and the purchaser, shall be written in the English language. However, the language of any printed literature furnished by the bidder in connection with its bid may be written in any other language provided the same is accompanied by an English translation and, for purposes of interpretation of the bid, the English translation shall prevail.

5. Bid Expense

- 5.1 The bidder shall bear all costs and expenditure incurred and/or to be incurred by it in connection with its bid including preparation, uploading of its bid and for subsequent processing the same. The purchaser will, in no case be responsible or liable for any such cost, expenditure etc regardless of the conduct or outcome of the Tender process.

B. TENDER ENQUIRY DOCUMENT

6. Content of Tender Enquiry Document

- 6.1 In addition to Section I – “Notice Inviting Tender” (NIT), the Tender Enquiry Document includes:
- Section II – General Instructions to Bidders (GIB)
 - Section III – Special Instructions to Bidders (SIB)
 - Section IV – General Conditions of Contract (GCC)
 - Section V – Special Conditions of Contract (SCC)
 - Section VI – Schedule of Requirements
 - Section VII – Specifications
 - Section VIII – Qualification Criteria
 - Section IX – Tender Acceptance Form
 - Section X – Price Schedules (BoQs)
 - Section XI – Bank Guarantee Form for Bid Security
 - Section XII – Bank Guarantee Form for Performance Security
 - Section XIII – Rate Contract Forms
 - Section XIV – Performa of Consignee Receipt Certificate
 - Section XV – Performa of Final Consignee Acceptance Certificate
 - Section XVI – List of items quoted
 - Section XVII – Performa to be filled by the tenderer
 - Section XVIII – Manufacturing & Marketing Certificate
 - Section XIX – Production Capacity Assessment Certificate

- 6.2 The relevant details of the required goods, the terms, conditions and procedure for Tender, bid evaluation, placement of Rate Contract/Purchase Order, the applicable contract terms and, also, the standard formats to be used for this purpose are incorporated in the above-mentioned documents. The interested bidders are expected to examine all such details etc to proceed further.

7. Corrigendum to Tender Enquiry Document

- 7.1 At any time prior to the deadline for submission of bids, the purchaser may, for any reason deemed fit by it, modify the Tender Enquiry Document by issuing suitable Corrigendum to it
- 7.2 Corrigendum will be notified through <https://eprocure.gov.in/eprocure/app> only.
- 7.3 In order to provide reasonable time to the prospective bidders to take necessary action in preparing their bids as per the amendment, the purchaser may, at its discretion extend the deadline appropriately for the submission of bids and other allied time frames, which are linked with that deadline.

8. Clarification of Tender Enquiry Document

- 8.1 A bidder requiring any clarification or elucidation on any issue of the Tender Enquiry Document may take up the same with the purchaser through CPP Portal only. The purchaser will respond through CPP Portal to such request provided the same is uploaded within the time schedule mentioned in “Critical Date Sheet”.

C. PREPARATION OF BIDS

9. Documents Comprising the Bid

- 9.1 The **Two Bid System**, i.e. “Techno – Commercial Bid” and “Price Bid” prepared by the bidder shall comprise the following:

A) Techno – Commercial Bid (Un-priced Bid)

- i) Scanned copy of “EMD/Bid Security” furnished in accordance with GIB alternatively, documentary evidence as per GIT for claiming exemption from payment of EMD/Bid security to be uploaded. THE EMD/BID SECURITY DEPOSITED AGAINST OTHER TENDERS CANNOT BE ADJUSTED OR CONSIDERED FOR THIS TENDER. NO INTEREST IS PAYABLE ON EMD/BID SECURITY. EMD/Bid Security of the approved firms, who fulfills pre-qualification requirements, would be retained till the firm is registered at AIIMS for the supply of Drugs/Medicines items.

FIRM WHICH HAD BEEN DECLARED ELIGIBLE ON THE BASIS OF PATENT/NICHE MOLECULE SHALL NOT BE EXEMPT UNDER THIS CLAUSE AND SHALL HAVE TO SUBMIT ALL DOCUMENTS AS PER THE REQUIREMENT OF THIS TENDER

- ii) Scanned copy of “List of Items Quoted” as per **SECTION – XVI** of Tender Enquiry Document.
- iii) Scanned copy of “Tender Acceptance Form” as per **Section IX** to be uploaded.
- iv) Scanned Copy of GST Registration Certificate.
- v) The Scanned Copies of following documents, wherever applicable may be uploaded under “Other Important Documents”:

- a) Scanned copy of Documentary evidence, as necessary in terms of clauses of GIB establishing that the bidder is eligible to submit the bid and, also, qualified to perform the Rate Contract if its bid is accepted to be uploaded.
 - b) Scanned copy of Power of Attorney in favor of signatory of Tender/Bid to be uploaded.
 - c) Scanned copy of Documents and relevant details to establish in accordance with GIB that the goods to be supplied by the bidder conform to the requirement of the Tender Enquiry Document to be uploaded.
 - d) Scanned copy of Documents confirming to Sole Proprietorship/ Partnership/Private Limited Firm in the country of origin as the case may be to be uploaded.
- vi) Scanned Copy of undertakings and Other Documents as per TED.

Note:

1. It is the responsibility of bidder to go through the Tender Enquiry Document to ensure uploading all required documents in addition to above, if any

B) Price Bid:

Price Schedule(s) as per BoQ format filled up with all the details including Make, Model etc. of the goods offered to be uploaded.

Schedule of price bid in the form of BOQ_XXXX .xls:

The below mentioned (Section X) price bid format is provided as BoQ_XXXX.xls along with this Tender Enquiry Document at <https://eprocure.gov.in/eprocure/app> . Bidders are advised to download this BoQ_XXXX.xls as it is and quote their offer/rates in the permitted column and upload the same in the commercial bid. Bidder shall not tamper/modify downloaded price bid template in any manner. In case if the same is found to be tempered/modified in any manner, tender will be completely rejected and tenderer is liable to be banned from doing business with AIIMS New Delhi.

- 9.2 The authorized signatory of the bidder must digitally sign the bid. Individuals digitally signing the bid or other documents connected with a Rate Contract must specify whether he signs as:
 - i) A 'Sole Proprietor' of the firm or constituted attorney of such Sole Proprietor.
 - ii) In case of partnership firm he must have authority to quote & to refer to arbitration dispute concerning the business of the partnership either by virtue of the partnership agreement or a power of attorney;
 - iii) Constituted attorney of the firm if it is a company.

Note:

- 1) In case of (ii) above, a copy of the partnership agreement duly registered with "Registrar of Firm's" or general power of attorney, in either, case, attested by a Notary Public should be uploaded, or affidavit on stamped paper of all the partners admitting execution of the partnership agreement or the general power of attorney should be uploaded.
- 2) In case of the partnership firms, where no authority to refer disputes concerning the business of the partnership has been conferred on any partner, the bid and all other related documents must be signed by every partner of the firm and uploaded.
- 3) Person digitally signing the Tender Acceptance Form or any documents forming part of the contract on behalf of another shall be deemed to warrantee that he has authority to bind such other persons and if, on enquiry, it appears that the persons so signing had no authority to do so, the purchaser may, without prejudice to other civil and criminal remedies, liable

for rejection of bid or cancel of contract and hold the signatory liable for all cost and damages.

- 9.3 A bid, which does not fulfill any of the above requirements and/or gives evasive information/reply against any such requirement, shall be liable to be ignored and rejected.
- 9.4 Bid sent by fax/email shall be ignored.

10. Bid Currencies

- 10.1 The bidder supplying indigenous goods or already imported goods shall quote only in Indian Rupees (INR).
- 10.2 Bids, where prices are quoted in any other way shall be treated as non -responsive and rejected.

11 Bid Prices

- 11.1 The Bidder shall indicate in the Price Schedule provided in BoQ all the specified components of prices shown therein including the unit prices on Free Delivery At Site basis, applicable GST, HSN Code, it proposes to supply against the requirement. The Bidders shall indicate MRP in the relevant column against each item of BoQ. The details about make & model, if applicable, may also be indicated. All the columns shown in the Price Schedule should be filled up as required.
- 11.2 In no case the quoted rates should be more than MRP at the time of submission of quotation. If subsequently during the currency of Rate Contract there is decreased in MRP, the bidder shall inform the purchaser promptly along with revised reduced rates on pro-rata basis. In case, if bidder quotes more than MRP and/or does not inform purchaser about reduction in MRP, it will be viewed seriously and appropriate administrative action will be taken including de-barring the firm.
- 11.3 If there is more than one schedule in the “Schedule of Requirements”, the bidder has the option to submit its bid for any one or more schedules. However, while quoting for a schedule, the bidder shall quote for the complete requirement of goods as specified in that particular schedule.
- 11.4 The need for indication of all such price components by the bidders, as required in this clause is for the purpose of comparison of the bids by the purchaser and will no way restrict the purchaser’s right to award the Rate Contract on the selected bidder on any of the terms offered.
- 11.5 In case of controlled drugs by the Government (Under DPCO), the quotation must be sent subject to the controlled rates and other conditions and supplier will be paid at the controlled price or rates offered by the supplier whichever is less. Controlled drugs must be clearly mentioned as such in the bidders’ quotations.

12. Firm Price

- 12.1 Prices quoted by the bidder shall remain firm and fixed during the currency of the Rate Contract and not subject to variation on any account. Purchase Orders will be placed by Centers/Hospital/Departments/Store Sections against this Rate Contract till the currency period of Rate Contract.
- 12.2 Statuary variation in GST will be applicable.

13. Alternative Models/Brands/Quality

- 13.1 Alternative Models/Brands/Quality are not permitted. The Bidders are required to quote Models/Brands/Quality of best quality meeting tender specifications. Wherever, a bidder quotes alternative Models/ Brands/ Quality, there bid will not be considered for that item.

14 Documents Establishing Bidder’s Eligibility and Qualifications

- 14.1 The bidder shall furnish, as part of its bid, relevant details and documents establishing its eligibility to quote and its qualifications to perform the Rate

Contract if its bid is accepted. The “Qualification Criteria” have been given in Section VIII.

- 14.2 Quotations shall be strictly according to the required specifications, and in the case of formulations, detailed formula along with the connected literature, Drug licenses etc. should be furnished. The name of the manufacturer and the brand name should also be stated.

15. Documents establishing good’s Conformity to Tender Enquiry Document.

- 15.1 The bidder shall upload in its bid the required as well as the relevant documents like technical data, literature, drawings etc. to establish that the goods offered in the bid fully conform to the goods specified by the purchaser in the Tender Enquiry Document. For this purpose, the bidder shall also upload a clause-by-clause commentary on the technical specifications and other technical details incorporated by the purchaser in the Tender Enquiry Document to establish technical responsiveness of the goods offered in its bid.
- 15.2 In case there is any variation and/or deviation between the goods prescribed by the purchaser and that offered by the bidder, the bidder shall list out the same in a chart form without ambiguity and provide the same along with its bid.
- 15.3 If a bidder furnishes wrong and/or misleading data, statement(s) etc. about technical acceptability of the goods offered by it, its bid will be liable to be ignored and rejected in addition to other remedies available to the purchaser in this regard.

16. Bid Security (BS) /EMD

- 16.1 Pursuant to the bidder shall furnish along with its bid, Bid Security for amount as shown in the Notice Inviting Tenders (NIT).
- 16.2 The original Earnest Money/Bid Security must be delivered to address as given in NIT till bid opening date and time as mentioned in “Critical Date Sheet” failing which the bid shall be summarily rejected. The scanned copy of original Bid Security/EMD may be uploaded along with the bid.
- 16.3 The bidders who are currently registered with MSME for the goods as per Tender document specification shall be eligible for exemption from Bid Security as defined in MSE Procurement Policy issued by the department of MSME. In case the bidder falls in this category, the bidder shall upload relevant certificate of registration for the subject goods issued by department of MSME.
- 16.4 The Bid Security shall be denominated in Indian Rupees. The Bid Security shall be furnished in one of the following forms:
- i) Account Payee Demand Draft/ Banker’s cheque
 - ii) Fixed Deposit Receipt
 - iii) Bank Guarantee
- 16.5 The demand draft or banker’s cheque shall be drawn on any commercial bank in India, in favour of as indicated in the NIT payable at New Delhi. In case of Bank Guarantee, the same is to be provided from any commercial bank in India or country of the bidder as per the format specified under Section XI in these documents.

- 16.6 The Bid Security shall be valid for a period of forty-five (45) days beyond the validity period of the bid. As validity period of Bid is 270 days, the Bid Security shall be valid for 315 days from Techno – Commercial Bid opening date.
- 16.7 The Bid Security of successful bidder will be returned without any interest, after receipt of performance security from that bidder.
- 16.8 Bid Security is required to protect the purchaser's right against the risk of the Bidder's conduct, which would warrant the forfeiture of the Bid Security. Bid Security of a bidder will be forfeited, if the bidder withdraws or amends its bids or impairs or derogates from the bid in any respect within the period of validity of its bid or if it comes to the notice that the information/documents furnished in its bid is incorrect, false, misleading or forged without prejudice to other rights of the purchaser. The Bid Security of the successful bidder will be forfeited without prejudice to other rights of Purchaser if it fails to furnish the required performance security within the specified period.

17. Bid Validity

- 17.1 The bid shall remain valid for acceptance for a period of 270 days (Two hundred and Seventy days) after the date of bid opening prescribed in the Tender Document. Any bid valid for a shorter period shall be treated as unresponsive and rejected.
- 17.2 In exceptional cases, the bidder may be requested by the purchaser to extend the validity of their bids up to a specified period. Such request(s) and responses thereto shall be conveyed by mail/fax/email. The bidders, who agree to extend the bid validity, are to extend the same without any change or modification of their original bid and they are also to extend the validity period of the Bid Security accordingly. A bidder, who may not agree to extend its bid validity after the expiry of the original validity period, their bid will not be considered further and the Bid Security furnished by them shall be returned.
- 17.3 In case the day up to which the bids are to remain valid falls on/ subsequently declared a holiday or closed day for the purchaser, the bid validity shall automatically be extended up to the next working day.

18. Instructions for Online Bid Submission and Registration on CPP Portal:

- 18.1 The bidders shall submit their online bids as per the instruction given for online bid process. The bidders are required to submit soft copies of their bids electronically on the CPP Portal, using valid Digital Signature Certificates. The instructions given below are meant to assist the bidders in registering on the CPP Portal, prepare their bids in accordance with the requirements and submitting their bids online on the CPP Portal. More information useful for submitting online bids on the CPP Portal may be obtained at: <https://eprocure.gov.in/eprocure/app>.
- 18.2. Registration on CPP Portal:
- Bidders are required to enrol on the e-Procurement module of the Central Public Procurement Portal (URL: <https://eprocure.gov.in/eprocure/app>) by clicking on the link "Online bidder Enrolment" on the CPP Portal which is free of charge.
 - As part of the enrolment process, the bidders will be required to choose a unique username and assign a password for their accounts.
 - Bidders are advised to register their valid email address and mobile numbers as part of the registration process. These would be used for any communication from the CPP Portal.

- iv) Upon enrolment, the bidders will be required to register their valid Digital Signature Certificate (Class II or Class III Certificates with signing key usage) issued by any Certifying Authority recognized by CCA India (e.g. Sify/nCode /eMudhra etc.), with their profile.
- v) Only one valid DSC should be registered by a bidder. Please note that the bidders are responsible to ensure that they do not lend their DSC's to others which may lead to misuse.
- vi) Bidder then logs in to the site through the secured log-in by entering their user ID / password and the password of the DSC / e-Token.

18.3. Searching for Tender Enquiry Document on CPP Portal:

- i) There are various search options built in the CPP Portal, to facilitate bidders to search active tenders by several parameters. These parameters could include Tender ID, Organization Name, Location, Date, Value, etc. There is also an option of advanced search for tenders, wherein the bidders may combine a number of search parameters such as Organization Name, Form of Contract, Location, Date, Other keywords etc. to search for a tender published on the CPP Portal.
- ii) Once the bidders have selected the tenders they are interested in, they may download the required documents / tender schedules. These tenders can be moved to the respective 'My Tenders' folder. This would enable the CPP Portal to intimate the bidders through SMS / e-mail in case there is any corrigendum issued to the tender document.
- iii) The bidder should make a note of the unique Tender ID assigned to each tender, in case they want to obtain any clarification / help from the Helpdesk.

18.4. Preparation of Bids for uploading on CPP Portal

- i) Bidder should take into account any corrigendum published on the tender document before submitting their bids.
- ii) Please go through the tender advertisement and the Tender Enquiry Document carefully to understand the documents required to be submitted as part of the bid. Please note the number of covers in which the bid documents have to be submitted, the number of documents - including the names and content of each of the document that need to be submitted. Any deviations from these may lead to rejection of the bid.
- iii) Bidder, in advance, should get ready the documents/BoQ to be uploaded as indicated in the Tender Enquiry Document and generally, they can be in PDF / XLS / RAR / DWF/JPG formats. Scanned documents to be uploaded may be scanned with 100 dpi with black and white option which helps in reducing size of the scanned document and resulting in fast uploading. It is the responsibility of the bidder to ensure that uploaded scanned documents are legible.
- iv) To avoid the time and effort required in uploading the same set of standard documents which are required to be submitted as a part of every bid, a provision of uploading such standard documents has been provided to the bidders. Bidders can use "My Space" or "Other Important Documents" area available to them to upload such documents. These documents may be directly submitted from the "My Space" area while submitting a bid, and need not be uploaded again and again. This will lead to a reduction in the time required for bid submission process.

19. Submission of Bids for uploading on CPP Portal

- 19.1 Bidder should log into the site well in advance for bid submission so that they can upload the bid in time i.e. on or before the bid submission time. Bidder will be responsible for any delay due to other issues.

- 19.2 The bidder has to digitally sign and upload the required bid documents one by one as indicated in the Tender Enquiry document.
- 19.3 Bidder has to select the payment option as “offline” to pay the Bid Security/ EMD as applicable and enter details of the instrument.
- 19.4 Bidder should prepare the Bid Security/EMD as per the instructions specified in the Tender Enquiry Document. The original should be posted/couriered/given in person to the concerned official, latest by the last date of bid submission or as specified in the Tender Enquiry Document. The details of the DD/any other accepted instrument, physically sent, should tally with the details available in the scanned copy and the data entered during bid submission time. Otherwise the uploaded bid will be rejected.
- 19.5 Bidders are requested to note that they should necessarily submit their financial bids in the format provided and no other format is acceptable. If the price bid has been given as a standard BoQ format with the tender document, then the same is to be downloaded and to be filled by all the bidders. Bidders are required to download the BoQ file, open it and complete the white coloured (unprotected) cells with their respective financial quotes and other details (such as name of the bidder). No other cells should be changed. Once the details have been completed, the bidder should save it and submit it online, without changing the filename. If the BoQ file is found to be modified by the bidder, the bid will be rejected.
- 19.6 The server time (which is displayed on the bidders’ dashboard) will be considered as the standard time for referencing the deadlines for submission of the bids by the bidders, opening of bids etc. The bidders should follow this time during bid submission.
- 19.7 All the documents being submitted by the bidders would be encrypted using PKI encryption techniques to ensure the secrecy of the data. The data entered cannot be viewed by unauthorized persons until the time of bid opening. The confidentiality of the bids is maintained using the secured Socket Layer 128 bit encryption technology. Data storage encryption of sensitive fields is done. Any bid document that is uploaded to the server is subjected to symmetric encryption using a system generated symmetric key. Further this key is subjected to asymmetric encryption using buyers/bid openers’ public keys. Overall, the uploaded tender documents become readable only after the tender opening by the authorized bid openers.
- 19.8 The uploaded Tender/Bid shall become readable only after the tender opening by the authorized bid openers.
- 19.9 Upon the successful and timely submission of bids (i.e. after Clicking “Freeze Bid Submission” in the portal), the portal will give a successful bid submission message & a bid summary will be displayed with the bid no. and the date & time of submission of the bid with all other relevant details.
- 19.10 The bid summary has to be printed and kept as an acknowledgement of the submission of the bid. This acknowledgement may be used as an entry pass for any bid opening meetings.
- 19.11 Assistance to Bidders for uploading CPP Portal:
- i) Any queries relating to the Tender Enquiry Document and the terms and conditions contained therein should be addressed to the Tender Inviting Authority for a tender or the relevant contact person indicated in the NIT.

- ii) Any queries relating to the process of online bid submission or queries relating to CPP Portal in general may be directed to the 24x7 CPP Portal Helpdesk

E. BID OPENING

20. Opening of Bids

- 20.1 E- Bids will be opened after due time and date and the bidders may check the status etc. on CPP Portal.
- 20.2 No change/alteration on plea of clerical or typographical error in rates or other terms in the tender will be permitted under any circumstances.
- 20.3 Withdrawal of the complete tender can be allowed but in such cases, the earnest money shall be forfeited in full.
- 20.4 Partial withdrawal (in respect of one or more items quoted) will not be allowed under any circumstances.

F. SCRUTINY AND EVALUATION OF BIDS

21. Basic Principle

- 21.1 Bids will be evaluated on the basis of the terms & conditions already incorporated in the Tender Enquiry Document, based on which bids have been received and the terms, conditions etc. mentioned by the bidders in their bids. No new condition will be brought in while scrutinizing and evaluating the bids.

22. Scrutiny of Bids

- 22.1 The Purchaser will examine the Bids to determine whether they are complete, whether any computational errors have been made, whether required Bid Securities have been furnished, whether the documents have been properly signed stamped and whether the Bids are generally in order.
- 22.2 The Purchaser's determination of a Bid's responsiveness is to be based on the contents of the Bid itself without recourse to extrinsic evidence.
- 22.3 The Bids will be scrutinized to determine whether they are complete and meet the essential and important requirements, conditions etc. as prescribed in the Tender Enquiry Document.
- 22.4 **PHARMACOPOEIAL SPECIFICATION:**
Pharmacopoeia' specifications i.e. IP/BP/USP should be clearly mentioned against each drug/constituent of the drug quoted as per the provisions of Drug and Cosmetics Act, 1945.
- 22.5 In the absence of submission of the following, a bid shall be declared non-responsive during the evaluation and will be ignored;
 - i) Tender Acceptance Form as per Section IX (signed & stamped) not uploaded.
 - ii) Bid validity is shorter than the required period.
 - iii) Required Bid Security (Amount, validity etc.)/exemption documents have not been uploaded as per stipulated provisions.
 - iv) Bidder has not agreed to give the required Performance Security of required amount in an acceptable form for due performance of the contract.
 - v) Bidder has not agreed to other essential condition(s) specially incorporated in the Tender document like terms of payment, liquidated damages clause, shelf life clause, warranty clause, dispute resolution mechanism, and applicable law.
 - vi) Poor/unsatisfactory past performance.

- vii) Bidders who stand de-registered/banned/blacklisted by any Central Govt. /State Govt. Ministries/AIIMS, New Delhi.
- viii) Bidder has not agreed to currency of Rate Contract period.
- ix) Bidder has not agreed for the delivery terms and delivery period.

22.6 INSPECTION OF FIRM'S PREMISES:

The Director or his nominee reserves the right for inspection of the pharmaceutical firms participating in the tenders, by officers appointed by the Director. They can carry out inspection for assessing the capacity/capability/eligibility of the firm to make supplies on the basis of rate-contract and to ensure that good manufacturing practices are being followed by the manufacturer. The decision of the Director shall be final in this regard.

23. Minor Infirmary/Irregularity/Non-Conformity

- 23.1 If during the evaluation, the purchaser finds any minor informality and/or irregularity and/or non-conformity in a bid, the purchaser will convey its observation on such 'minor' issues, which has not price implication, to the bidders by registered/speed post/ e-mail/fax etc. asking the bidder to respond by a specified date. If the bidder does not reply by the specified date or gives evasive reply without clarifying the point at issue in clear terms, that bid will be liable to be ignored.

24. Qualification Criteria

- 24.1 Bids of the bidder, who have not uploaded required documents or do not meet the required Qualification Criteria prescribed in Section VIII, will be treated as non-responsive and will not be considered further.

25. Item-wise Evaluation

- 25.1 In case the Schedule of Requirements contains multiple items, the responsive bids will be evaluated and compared separately for each item.

26. Comparison of Bids

- 26.1. The comparison of the responsive Bids shall be carried out on Free Delivery at consignee site basis.

27. Purchase Preference for Evaluation

- 27.1 The Purchaser reserves the right to give the price preference to small-scale sectors etc. and purchase preference to central public sector undertakings as per the instruction in vogue while evaluating, comparing and ranking the responsive Bids.

28. Bidder's capability to perform the Rate Contract

- 28.1 The purchaser, through the above process of bid scrutiny and bid evaluation will determine to its satisfaction whether the bidder, whose bid has been determined as the lowest evaluated responsive bid is eligible, qualified and capable in all respects to perform the Rate Contract satisfactorily.
- 28.2 The above-mentioned determination will, inter alia, take into account the bidder satisfying all the requirements of the purchaser as incorporated in the Tender Enquiry Document. Such determination will be based upon scrutiny and examination of all relevant data and details submitted by the bidder in its bid as well as such other allied information as deemed appropriate by the purchaser.

29. Contacting the Purchaser

- 29.1 From the time of submission of bid to the time of awarding the Rate Contract, if a bidder needs to contact the purchaser for any reason relating to NIT/Tender Enquiry Document and / or its bid, it should do so only through CPP portal.
- 29.2 In case a bidder attempts to influence the purchaser in the purchaser's decision on scrutiny, comparison & evaluation of bids and awarding the contract, the bid

of the bidder shall be liable for rejection in addition to appropriate administrative actions being taken against that bidder, as deemed fit by the purchaser.

G. AWARD OF RATE CONTRACT

30. Purchaser's Right to accept any bid and to reject any or all bids.

- 30.1 The purchaser reserves the right to accept in part or in full any bid or reject any or more bid(s) without assigning any reason or to cancel the Tender process and reject all bids at any time prior to award of Rate Contract , without incurring any liability, whatsoever to the affected bidder(s).

31. Award Criteria

- 31.1 Subject to the above, the Rate Contract will be awarded to the lowest evaluated responsive bidder decided by the purchaser. In cases where advance samples have been called in "Special Instructions to Bidders" in Section III,

32. Purchase Orders to be placed during currency of Rate Contract

- 32.1 Purchase Orders will be placed from time to time by the Centers/Hospitals/Department/ Store Sections of AIIMS during the currency of Rate Contract, as per actual requirement, in which the exact quantities required on each occasion together with the date of delivery shall be specified in the purchase order.

33. Notification of Award

- 33.1 Before expiry of the bid validity period, the purchaser will notify the successful bidder (s) in writing, by registered / speed post or by fax/ email (to be confirmed by registered / speed post) that its bid for Goods, which have been selected by the purchaser, has been accepted, also briefly indicating there in the essential details like description, specification and quantity of the goods and corresponding prices accepted. The successful bidder must furnish to the purchaser the required Performance Security within thirty days from the date of dispatch of this notification, failing which the Bid Security will be forfeited and the award will be cancelled. Relevant details about the Performance Security have been provided in clause 3 of GCC under Section IV.
- 33.2 The Notification of Award shall constitute the conclusion of the Rate Contract.

34. Issue of Rate Contract

- 34.1 Promptly after notification of award, the Purchaser will mail the Rate Contract form (as per Section XIII) duly completed and signed, in duplicate, to the successful bidder by registered / speed post.
- 34.2 Within twenty one days from the date of the Rate Contract, the successful bidder shall return the original copy of the Rate Contract, duly signed and dated, to the Purchaser/ by registered / speed post/courier.

35. Non-receipt of Performance Security by the Purchaser

- 35.1 Failure of the successful bidder in providing Performance Security and / or returning Rate Contract copy duly signed in terms of GIB clauses above shall make the bidder liable for forfeiture of its Bid Security and, also, for further actions by the Purchaser it as per the clause 12-Termination of default of GCC under Section IV.

36. Return of Bid Security/EMD

- 36.1 The Bid Security/EMD of the successful bidder and the unsuccessful bidder will be returned to them without any interest, whatsoever, in terms of Clause 19 of GIB.

37. Publication of Bid Result

- 37.1 The name and address of the successful bidder(s) receiving the Rate Contract(s) will be mentioned in the CPP Portal.

H. CORRUPT OR FRAUDULENT PRACTICES

38. Corrupt or Fraudulent Practices

- 38.1 It is required by all concerned namely the Bidder /Suppliers/ Purchaser/Consignee/End User etc. to observe the highest standard of ethics during the procurement and execution of such Rate Contract/Purchase Orders. In pursuance of this policy, the Purchaser: -
- a) defines, for the purposes of this provision, the terms set forth below as follows:
 - i) “corrupt practice” means the offering, giving, receiving or soliciting of anything of value to influence the action of a public official in the procurement process or in Rate Contract/Purchase Orders execution; and
 - ii) “fraudulent practice” means a misrepresentation of facts in order to influence a procurement process or the execution of a Rate Contract/Purchase Orders to the detriment of the Purchaser, and includes collusive practice among bidders (prior to or after Bid submission) designed to establish Bid prices at artificial non-competitive levels and to deprive the Purchaser of the benefits of free and open competition;
 - b) Will reject a proposal for award if it determines that the Bidder recommended for award has engaged in corrupt or fraudulent practices in competing for the Rate Contract/Purchase Orders in question;
 - c) Will declare a firm ineligible, either indefinitely or for a stated period of time, to be awarded a Rate Contract/Purchase Orders by the purchaser if it at any time determines that the firm has engaged in corrupt or fraudulent practices in competing for, or in executing the Rate Contract/Purchase Orders.

SECTION – III
SPECIAL INSTRUCTIONS TO BIDDERS (SIB)

The following Special Instructions to Bidders will apply for this purchase. These special instructions will modify/substitute/supplement the corresponding General Instructions to Bidders (GIB) incorporated in Section II. The corresponding GIB clause numbers have also been indicated in the text below:

In case of any conflict between the provision in the GIB and that in the SIB, the provision contained in the SIB shall prevail.

Sl. No.	GIB Clause No.	Topic	SIB Provision
1.	1 - 38		No Change

1. If required, the bidder will submit the samples for each item in original packing, duly labeled (Printed) and sealed having date of manufacturing, date of Expiry, manufactured by with batch No. Stores Officer (H) within 10 days. If the bidder fails to submit the sample within given time, the bid will be summarily rejected and no correspondence will be entertained in this regard.

SECTION - IV
GENERAL CONDITIONS OF CONTRACT (GCC)

1. Application

- 1.1 The General Conditions of Contract incorporated in this section shall be applicable for this purchase to the extent the same are not superseded by the Special Conditions of Contract prescribed under Section V, Schedule of Requirements under Section VI and Technical Specification under Section VII of this document.

2. Patent Rights

- 2.1 The supplier shall, at all times, indemnify and keep indemnified the purchaser, free of cost, against all claims which may arise in respect of goods to be provided by the supplier under the Rate Contract/Purchase Orders for infringement of any intellectual property rights or any other right protected by patent, registration of designs or trademarks. In the event of any such claim in respect of alleged breach of patent, registered designs, trademarks etc. being made against the purchaser, the purchaser shall notify the supplier of the same and the supplier shall, at his own expenses take care of the same for settlement without any liability to the purchaser.

3. Performance Security

- 3.1 Within Thirty (30) days from date of the issue of Notification of Award by the Purchaser, the supplier shall furnish Performance Security to the Purchaser for an amount equal to three percent (3%) of the Total Estimated Quantity of the items for which Rate Contract is being awarded.
- 3.2 The Performance Security shall be denominated in Indian Rupees in any of the following forms:
- i) Account Payee Demand Draft
 - ii) Fixed Deposit Receipt drawn from any Scheduled bank in India
 - iii) Bank Guarantee issued by a Scheduled bank in India, in the prescribed form as provided in Section XII of this document
- 3.3 In the event of any failure /default of the supplier with or without any quantifiable loss to the government, the amount of the Performance Security is liable to be forfeited equivalent to the amount of Supply Order. The needful will be done to cover any failure/default of the supplier with or without any quantifiable loss to the Government.
- 3.4 In the event of any extension of currency of Rate Contract, the supplier shall, within fifteen (15) days of issue of the amendment, furnish the corresponding amendment to the Performance Security (as necessary), rendering the same valid in all respects in terms of the Rate Contract , as amended.
- 3.5 Subject to above, the Purchaser will release the Performance Security without any interest to the supplier on completion of the supplier's all contractual obligations including the warranty obligations (if applicable).

4. Technical Specifications

- 4.1 The Goods to be provided by the supplier under this Rate Contract shall conform to the 'Technical Specification' under Sections VII of this document.

5. Inspection, Testing and Quality Control

- 5.1 The purchaser has contractual right to inspect, test and, if necessary, reject the goods to confirm their conformity to the Rate Contract specifications and other quality control details incorporated in the Rate Contract.
- 5.2 If during such inspections and tests the contracted goods fail to conform to the required specifications and standards, the purchaser may reject them and the supplier shall either replace the rejected goods or make all alterations necessary to meet the specifications and standards, as required, free of cost to the purchaser and re-submit the same to the purchaser for conducting the inspections and tests again. No payment shall be made for rejected material and In case rejected goods are not removed, these will be disposed off in a manner as deemed fit by the authorities at the risk and responsibility of the suppliers without any further notice.
- 5.3 Regular and random testing of drugs will be under taken by AIIMS from any NABL accredited /Govt. approved laboratories (Annexure attached) at the time of supply and at any time during the shelf life or whenever any defect is noticed. The Director AIIMS shall be at liberty to undertake regular and random testing of the drugs supplied by the pharmaceutical firm/ bidder at regular interval to maintain and ensure the quality of drugs.
- 5.4 The report of the NABL accredited/Govt. approved laboratory shall be accepted by the pharmaceutical firm. In case the same is disputed by the pharmaceutical firm, the report of the approved Central Drug Testing Laboratory as approved by CDSCO (Appellate Authority) only will be accepted as final. However, the same should be submitted within three months, from the date of communication of the disputed test report to the pharmaceutical firm. For this, the pharmaceutical firm should approach the concerned Drug Control Authorities for getting the drugs tested, as per procedure.
- 5.5 If any drug sample fails the test or is found to be of substandard quality, action as below will be initiated:
 - (a) If any store/stores supplied against the contract are found to be not of standard quality as per specifications on analysis and/or on inspection by competent authority, the Institute will destroy the entire consignment against the particular invoice, irrespective of fact that part of the supplied stores may have been consumed. The institute shall not be liable to make any payments in lieu of inferior items.
 - (b) If the firm fails to make fresh supplies in lieu of substandard quality of drug, it is liable to be debarred for three years in respect of all the items in the rate-contract of this Institute and EMD/Performance security shall be forfeited.
 - (c) If the product is found to be not of standard quality, the cost of testing done by the Institute will be recovered from the supplier.
 - (d) In case, the supplies are found to be of inferior quality on three occasions, the firm shall be liable for debarment for subsequent tender of Drugs and EMD/Performance security shall be forfeited.
 - (e) A copy of the test report will be sent to the DCGI for necessary action at their end.

- (f) If any drugs supplied against this Rate Contract are found to be not of standard quality on inspection by Competent Authority, the pharmaceutical firm will be liable to replace the entire quantity within 15 days otherwise risk purchase will be charged from the company and the cost of testing will be recovered from the supplier.
- 5.6 Goods accepted by the purchaser/consignee in inspection in terms of the Rate Contract/Purchase Orders shall in no way dilute purchaser's/consignee's right to reject the same later, if found deficient in terms of the warranty clause, if applicable.

Quality Control

- I. The stores offered should comply with the provisions of the Drugs and Cosmetics Act, 1940 and the Rules made there under as and Drug Price Control order.
- II. While quoting against items with ISI Mark, it should be ensured that ISI code number is indicated on quotation and at the time of making the supplies, the pharmaceutical firm should ensure that the items supplied has ISI Mark as well as Code Number, as is the statutory requirement of the Bureau of Indian Standards. The attested copy of the valid ISI Marking license issued by Bureau of Indian Standards should be enclosed along with the quotation.

6. Terms of Delivery

- 6.1 Goods shall be delivered by the supplier on "Free Delivery At Site" basis and delivered as per Delivery Period specified in the Purchase Order placed against Rate Contract. Please note that the time shall be the essence of the contract.
- 6.2 The goods are to be supplied by F.O.R. destination and all the transit loss/expenses whatsoever, will be borne by the supplier/firm.

7. Warranty

- 7.1 The supplier warrants comprehensively that the goods supplied under the Rate Contract is new, unused and incorporate all recent improvements in design and materials unless prescribed otherwise by the purchaser in the Rate Contract. The supplier further warrants that the goods supplied under the Rate Contract/Purchase Orders shall have no defect arising from design, materials or workmanship or from any act or omission of the supplier that may develop under normal use of the supplied goods under the conditions prevailing in India.
- 7.2 The warranty period (if applicable as stated in Schedule of Requirement in Section-VI or Technical Specification in Section- VII) shall include all spares, labor and preventive maintenance from the date of completion of the satisfactory installation and acceptance till warranty period.

8. Prices

- 8.1 Prices quoted by the bidder shall remain firm and fixed during the currency of the Rate Contract and not subject to variation on any account. Purchase Orders will be placed by Centers/Hospital/Departments/Store Sections against this Rate Contract till the currency period of Rate Contract.
- 8.2 Statuary variation in GST will be applicable during currency of the contract, during the original Delivery Period of Purchase Order after

submitting supporting documents (Government notifications) issued by concern department.

- 8.3 **Rate Revision:** Successful bidders shall not be entitled to any rate-revision of price for any reason except Govt. levies which become applicable after finalization of rate contract along with adequate documentary proof thereof.

9. Payment Terms

- 9.1 100% payment would be made on receipt of goods in good condition and acceptance, upon the submission of the following documents:
- i) Original copies of supplier's invoice showing Rate Contract/Purchase Orders number, goods description, quantity, packing list, unit price and total amount;
 - ii) "Consignee Receipt Certificate" as per Section XIV of Tender document in original
 - iii) "Final Consignee Acceptance Certificate" as per Section XV of goods to be issued by the End User subject to recoveries, if any, either on account of non-rectification of defects/deficiencies not attended by the Supplier or otherwise.
- 9.2 Any dues or payments that have arisen to the Institution from the supplier for which no specific time-limit has been laid down in the terms & conditions, shall be payable by the supplier within such time limit as may be prescribed in the various letters/orders addressed to the contractors. On failure to do so the supplier shall be liable to be debarred for not paying dues or payment etc. to the hospital for a period as decided by the Director or his nominee.
- 9.3 Conditions of advance payments or payment against delivery shall not be accepted.

10. Delivery

- 10.1 The supplier shall deliver the goods under the Rate Contract within the time schedule specified by the Purchaser Order as per in the Schedule of Requirements and as incorporated in the Rate Contract. The time for and the date of delivery of the goods stipulated in the Purchase Order shall be deemed to be of the essence of the contract and the delivery must be completed no later than the date (s) as specified in the Purchase Order.
- 10.2 Supply orders placed against the contract, on or just before last date of the tenure of contract will have to be accepted /honored by the supplier.
- 10.3 **No guarantee can be given as to the minimum quantity which will be demanded against this contract, but the supplier will supply such quantity as may be ordered by the Stores Officer during the tenure of the contract.**
- 10.4 Subject to the provision under Force Majeure clause of GCC, any unexcused delay by the supplier in maintaining its contractual obligations towards delivery of goods shall render the supplier liable to any or all of the following sanctions:
- i) Imposition of liquidated damages,
 - ii) Forfeiture of its Performance Security and
 - iii) Termination of the Rate Contract/Purchase Orders for default.

- 10.5 If at any time during the currency of the Rate Contract, the supplier encounters conditions hindering timely delivery of the goods, the supplier shall promptly inform the Purchaser in writing but not later than 10 days from the date of issue of the Purchase Order about the same and its likely duration and make a request to the Purchaser for extension of the delivery schedule accordingly. In case no communication is received within 10 days from the date of issue of Purchase Order, it will be presumed that supplier has accepted the Purchase Order in all regards. On receiving the supplier's communication, the Purchaser shall examine the situation as soon as possible and, at its discretion, may agree to extend the delivery schedule, with or without liquidated damages for completion of supplier's contractual obligations by issuing an amendment to the Purchase Order.
- 10.6 When the period of delivery is extended due to unexcused delay by the supplier, the amendment letter extending the delivery period shall, inter alia contain the following conditions:
- i) The Purchaser shall recover from the supplier, under the provisions of the Force Majeure clause of the General Conditions of Contract, Liquidated Damages on the goods, which the Supplier has failed to deliver within the delivery period stipulated in the Purchase Order.
 - ii) That no increase in price on account of any ground, whatsoever, including any stipulation in the Rate Contract for increase in price on any other ground and, also including statutory increase in or fresh imposition of GST levied in respect of the goods specified in the Purchase Order, which takes place after the date of delivery stipulated in the Purchase Order shall be admissible on such of the said goods as are delivered and performed after the date of the delivery stipulated in the Purchase Order.
 - iii) But nevertheless, the Purchaser shall be entitled to the benefit of any decrease in price on account of reduction in GST which takes place after the expiry of the date of delivery stipulated in the Purchase Order.
- 10.7 The supplier shall not dispatch the goods after expiry of the delivery period. The supplier is required to apply to the Purchaser for extension of delivery period and obtain the same before dispatch. In case the supplier dispatches the goods without obtaining an extension, it would be doing so at its own risk and no claim for payment for such supply and / or any other expense related to such supply shall lie against the purchaser.
- 10.8 Passing of Property
- (i) The property in the goods shall not pass to the purchaser unless and until the goods have been delivered to the consignee in accordance with the contract.
 - (ii) Where there is a contract for sale of specific goods and the supplier is bound to do something to the goods for the purpose of putting them into a deliverable state the property does not pass until such thing is done.
 - (iii) Unless otherwise agreed, the goods remain at the supplier's risk until the property therein is transferred to the purchaser.

- 10.9 The delivery period should not exceed 45 (forty five) days for all supplies but in emergency the delivery period may be reduced up to 15 days and firm is bound to supply the items within DOD (Date of delivery) period. Bidders are hereby directed to quote the rates of only those drugs/medicines for which they can ensure supply within 45 days of issue of supply-order along with Test Report either on Form 39 from Govt. approved analytical testing laboratory or from in house Test Lab (approved by NABL (National Accreditation Board for Testing and Calibration Laboratories or GLP (Good Lab Practice) accredited Lab. without which the supply will not be accepted. It will be the responsibility of the vendor to provide the certificate of NABL/GLP accredited of the laboratory from which the test report is given. In case the total value of supply order of drugs is less than Rs.-10,000/- in house Lab Test Report will be accepted. However, AIIMS reserves the right to get the supplies tested again from a Govt. /NABL accredited laboratory. In case of failure to either supply the goods within DOD (Date of delivery) period or if goods are not accompanied with lab. test report, they may be debarred, after three defaults, from participating in the next tender for a period of three years and their EMD/ Bid Security/Performance Security Money may be forfeited and risk purchase clause will be invoked. However, in case of imported drugs, In house Test Report of the manufacturing Company will be accepted.
- 10.10 Supply time: Timing 2.00 P.M to 4.00 P.M (from Monday to Friday) & 11.00 A.M to 12.00 Noon (on Saturday).
- 10.11 Before making the supply, approved rate contract holder should ensure that all labels of cartons, ampoules, vials, bottles, jars, tubes etc. should be embossed, imprinted, stamped with letters, other requirements like “AIIMS SUPPLY NOT FOR SALE” stamp with permanent ink on each item/strip up to primary level. The supply Challan should be accompanied by test report from NABL accredited lab/Govt. Approved Lab. While delivering the supplies, the firm will ensure that quantities are as per challan, quality of material is as per Rate contract specifications etc. All the items which are stamped with “AIIMS SUPPLY NOT FOR SALE” mark, including rejected stores, cannot be sold to the public by the bidder.
- 10.12 The supplier shall arrange to effect free replacement of any quantity which may deteriorate in potency, strength approaching expiry or expired etc. before the date of expiry marked on the labels.
- 10.13 If the supplied item is not utilized before expiry date the supplier should undertake to replace with fresh stock of items as and when required.
- 10.14 MARKING: Each packing shall be marked with nomenclature of the drug and shall be labeled in accordance with the requirement of the Drugs and Cosmetics Act, 1940 and the rules made there under.
- 10.15 **PACKING:**
- 1) Tendering firms must quote for the packing specified against each item in the schedule annexed to the rate-enquiry, as any other packing may not be accepted.
 - 2) Where no pack is specified, bidders may quote for standard pack which is available in the market.
 - 3) Loose supplies / damaged packing / tampered or damaged labeled supplies shall not be accepted under any circumstances.
 - 4) Rates should be quoted for strip packing only except where mentioned.
 - 5) Supplies to be made in the box of Standard packing. However tablets/capsules in loose pack (tin/bottle) shall not be accepted.

- 6) Liquid orals to be supplied only in glass / plastic bottles conforming to IP/BP/USP/Drugs & Cosmetics Act, 1940.
 - 7) Large volume parenteral to be quoted and supplied only in glass/plastic bottles / poly packs conforming to I.P. /BP/USP/ Drug & Cosmetic Act, 1940.
 - 8) It should be ensured that only first use packaging material of uniform size including bottles and vials, is used for making supplies on the basis of rate-contract.
 - 9) All primary packing containers should be strictly conforming to the specification included in the relevant pharmacopoeia.
 - 10) Packing should be able to prevent damage or deterioration during transit.
 - 11) All containers i.e. bottles, cartons, tubes etc. are required to be secure with pilferage-proof seals to ensure genuineness of the products packed and the correctness of the contents. MRP should not be written/embossed/should be defaced with indelible ink on any labels otherwise it will be disqualified for that supply.
- 10.16 The supply offered should comply with the provisions of the Drugs and Cosmetics Act, 1940 and the Rules made there under as amended up to date and Drug Price Control order.

11. Liquidated Damages

11.1 PENALTY FOR NON-SUPPLY/LATE SUPPLY

- i) Subject to Force Majeure clause of the General Conditions of Contract, if the supplier fails to deliver any or all of the goods within the time frame(s) incorporated in the Purchase Order, the Purchaser shall, without prejudice to other rights and remedies available to the Purchaser under the Rate Contract, deduct from the Purchase Order, as liquidated damages, a sum equivalent to 0.5% per week of delay or part thereof on delayed supply of goods, until actual delivery or performance subject to a maximum of 10% of the Purchase Order price. Once the maximum is reached Purchaser may consider termination of the Purchase Order as per GCC.
 - ii) If supplier fails to execute the supply order three times during the period of rate contract, it shall be debarred for the next three years with effect from the last failure and forfeiting of Performance Security for that drug
- 11.2 In case of default institute will have the right to procure the ordered item from open market /another party at their own risk and expenses under risk purchase clause.
- 11.3 The approved rate contract holders should supply all their ordered items within DOD period as per supply order terms and these terms should be strictly adhered to. **In case they fail to supply the item within DOD period, the reminder letter would not be issued in any circumstances and penalty will be imposed.** The item would be arranged either through local purchase or from open market under Risk Purchase Clause without any information in this regard. The difference amount shall be recovered from the pending dues of the firm. **In the eventuality of such instances being repeated, administrative action shall be initiated as per AIIMS procedure which may lead to debarring of the firm for subsequent tenders (up to 3 years).**
- 11.4 It is hereby also informed that in case any administrative action (imposing of liquidated damages, warning letter, risk purchase, short supply etc.) is taken by the AIIMS during the rate contract period against any approved

vendor, it would be reflected during finalization of the next rate contract as “Past performance” of that firm.

- 11.5 The Director or his nominee reserves the right to invite at his sole discretion, separate quotations to effect purchase outside this contract in the event of any urgent demand arising in hospital, where no stock is held or otherwise.

12. Termination for Default

- 12.1 The Purchaser without prejudice to any other contractual rights and remedies available to it the Purchaser, may, by written notice of default sent to the supplier, terminate the Rate Contract and/or Purchase Order in whole or in part, if the supplier fails to deliver any or all of the goods or fails to perform any other contractual obligation(s) within the time period specified in the Purchase Order, or within any extension thereof granted by the Purchaser.
- 12.2 The Performance Security in such cases will be forfeited equivalent to the amount of Purchase Order.
- 12.3 Unless otherwise instructed by the Purchaser, the supplier shall continue to perform the Rate Contract/Purchase Orders to the extent not terminated.

13. Termination for Insolvency

- 13.1 If the supplier becomes bankrupt or otherwise insolvent, the purchaser reserves the right to terminate the Rate Contract/Purchase Orders at any time, by serving written notice to the supplier without any compensation, whatsoever, to the supplier, subject to further condition that such termination will not prejudice or affect the rights and remedies which have accrued and / or will accrue thereafter to the Purchaser.

14. Force Majeure

- 14.1 Notwithstanding the provisions contained in above clauses of GCC, the supplier shall not be liable for imposition of any such sanction so long the delay and/or failure of the supplier in fulfilling its obligations under the Rate Contract/Purchase Orders is the result of an event of Force Majeure.
- 14.2 For purposes of this clause, Force Majeure means an event beyond the control of the supplier and not involving the supplier's fault or negligence and which is not foreseeable and not brought about at the instance of the party claiming to be affected by such event and which has caused the non – performance or delay in performance. Such events may include, but are not restricted to, wars or revolutions, hostility, acts of public enemy, civil commotion, sabotage, fires, floods, explosions, epidemics, quarantine restrictions, strikes excluding by its employees, lockouts excluding by its management and freight embargoes.
- 14.3 If a Force Majeure situation arises, the supplier shall promptly notify the Purchaser in writing of such conditions and the cause thereof within twenty one days of occurrence of such event. Unless otherwise directed by the Purchaser in writing, the supplier shall continue to perform its obligations under the Rate Contract/Purchase Orders as far as reasonably practical, and shall seek all reasonable alternative means for performance not prevented by the Force Majeure event.

- 14.4 If the performance in whole or in part or any obligation under this Rate Contract/Purchase Orders is prevented or delayed by any reason of Force Majeure for a period exceeding sixty days, either party may at its option terminate the Rate Contract/Purchase Orders without any financial repercussion on either side.
- 14.5 In case due to a Force Majeure event the Purchaser is unable to fulfill its contractual commitment and responsibility, the Purchaser will notify the supplier accordingly and subsequent actions taken on similar lines described in above sub-paragraphs.

15. Termination for Convenience

- 15.1 The Purchaser reserves the right to terminate the Rate Contract, in whole or in part for its Purchaser's convenience, by serving written notice on the supplier of 30 days at any time during the currency of the Rate Contract.
- 15.2 The Supplier reserves the right to terminate the Rate Contract, in whole or in part for its Purchaser's convenience, by serving written notice by the supplier of 90 days at any time during the currency of the Rate Contract.

16. Resolution of Disputes

- 16.1 If dispute or difference of any kind shall arise between the Purchaser/Consignee and the supplier in connection with or relating to the Rate Contract/Purchase Orders, the parties shall make every effort to resolve the same amicably by mutual consultations.
- 16.2 If the parties fail to resolve their dispute or difference by such mutual consultation within twenty-one days of its occurrence, then, unless otherwise provided in the SCC, either the Purchaser/Consignee or the supplier may give notice to the other party of its intention to commence arbitration, as hereinafter provided the applicable arbitration procedure will be as per the Arbitration and Conciliation Act, 1996 of India.
- 16.3 In the case of a dispute or difference arising between the Purchaser and a domestic Supplier relating to any matter arising out of or connected with the Rate Contract/Purchase Orders, such dispute or difference shall be referred to the sole arbitration to be appointed by the Director, AIIMS. The award of the arbitrator shall be final and binding on the parties to the Rate Contract/Purchase Orders subject to the provision that the Arbitrator shall give reasoned award in case the value of claim in reference exceeds Rupees One lakhs (Rs. 1,00,000/-)
- 16.4 Venue of Arbitration: The venue of arbitration shall be the place from where the Rate Contract/Purchase Orders has been issued, i.e., New Delhi, India.
- 16.5 Jurisdiction of the court will be from the place where the Tender Document has been issued, i.e., New Delhi, India.
- 16.6 Applicable Law: The Rate Contract/Purchase Orders shall be governed by and interpreted in accordance with the laws of India for the time being in force.

17 Withholding and Lien in respect of sums claimed

- 17.1 Whenever any claim for payment arises under the Rate Contract/Purchase Orders against the supplier the purchaser shall be entitled to withhold and also have a lien to retain such sum from the security deposit or sum of money arising out of under any other Rate Contract/Purchase Orders made by the supplier with the purchaser, pending finalization or adjudication of any such claim.
- 17.2 It is an agreed term of the Rate Contract/Purchase Orders that the sum of money so withheld or retained under the lien referred to above, by the purchaser, will be kept withheld or retained till the claim arising about of or under the Rate Contract/Purchase Orders is determined by the Arbitrator or by the competent court as the case may be and the supplier will have no claim for interest or damages whatsoever on any account in respect of such withholding or retention.

SECTION – V
SPECIAL CONDITIONS OF CONTRACT (SCC)

The following Special Conditions of Contract (SCC) will apply for this purchase. The corresponding clauses of General Conditions of Contract (GCC) relating to the SCC stipulations have also been incorporated below.

These Special Conditions will modify/substitute/supplement the corresponding (GCC) clauses.

Whenever there is any conflict between the provision in the GCC and that in the SCC, the provision contained in the SCC shall prevail.

The warranty conditions, Shelf life, if applicable, will be as mentioned in the Schedule of Requirement as per section VI of the Tender Enquiry Document.

- 1. The quantity shown in the tender can be increased or decreased to any extent depending upon the actual requirement.**

SECTION – VI
SCHEDULE OF REQUIREMENTS
As per “Annexure A”- List of Drugs/Molecules

Terms of Delivery:

Free Delivery at Consignee's Site(s)

1. Delivery Period:

- 1.1 The Delivery Period is maximum 45 days from date of issue of Purchase Order against the Rate Contract. In case of exigency, a shorter Delivery Period can be given and if, it is not acceptable to Supplier, it may be intimated to the Purchase Officer within seven days from the date of issue of the Purchase Order, otherwise it will be assumed that the Purchase Order has been accepted. The date of delivery will be the date by when it is to be delivered at consignee site.
- 1.2 The purchaser will not pay separately for transit insurance and the contractor will be responsible for delivery of items covered by the supply-order in good condition at the specified destination and for this purpose, freight, insurance, octroi etc., if any will have to be borne by the supplier. The consignee will, as soon as possible, but not later than 07 days of the date of arrival of stores at destination, notify the supplier/ bidder, of any loss or damage to the stores that may have occurred in the transit.

2. Shelf-Life:

- a) Short- life items (which have a life-period of eighteen months or less), should not have passed 5/6th of their total shelf life at the time of supply.
- b) In respect of items not covered by clause (i) above, stores should not be older than one year from the date of manufacturing at the time of supply.
- c) For all those drugs, which are required to be stored under controlled temperature / cold chain, have to be supplied under controlled temperature/cold chain.
- d) If the supplied item is not utilized before expiry date the supplier should undertake to replace with fresh stock of items as and when required.
- e) The supplier shall arrange to effect free replacement of any quantity which may deteriorate in potency, strength approaching expiry or expired etc. before the date of expiry marked on the labels.
- f) For Drugs having shelf life of Two years or less: As on the date of delivery, Drugs should not be older than one fourth (1/4) of its shelf life from the date of manufacture.
- g) For Drugs having shelf life more than Two years: As on the date of delivery, Drugs should not be older than one sixth (1/6) of its shelf life from the date of manufacture.
- h) For Imported Drugs: As on the date of delivery, Drugs should have a minimum 50% of valid shelf life from the date of manufacture.

However, the consignee may relax this criteria in case of exigencies with reasons duly recorded and shall be responsible for use of that stores within its given shelf life, with a suitable undertaking from the supplier, the terms of which shall be decided by the consignee as per the requirement of the stores and usage pattern. The Consignee should ensure that there should not be any loss to the Corporation.

3. The supply offered should comply with the provisions of the Drugs and Cosmetics Act, 1940 and the Rules made there under as amended up to date and Drug Price Control order.

(ii) While making quotations against re-packing and chemical items, it must be ensured that ISI code number is indicated on quotation and at the time of making the supplies, the firm should ensure that the item supplied has ISI mark as well as code number, as is the statutory requirement of the Bureau of Indian Standards. The attested copy of the valid ISI marking license issued by Bureau of Indian Standards should be enclosed along with quotation.

If a molecule is being repacked all the requirements of 28 (i) to (xviii) must be fulfilled for the repacked molecule.

For delayed delivery, liquidated damages will get applied as per GCC.

SECTION – VII
SPECIFICATION
As per “Annexure A”- List of Drugs/Molecules

Section – VIII

Qualification Criteria

1. Scanned copy of **Manufacturing & Market standing/ experience certificate** of minimum **“Three Years”** of the molecule quoted by them duly certified by centre/ State Drug Controller in the Performa Section- XVIII. The certificate should have been issued recently i.e. not more than one year old from the date of the opening of the tender.
2. WHO GMP/GMP Certificate Scanned Copy of Valid WHO-GMP certificate/ Valid Schedule ‘M’ certificate issued by Centre/ State Drug Controller and should not have been issued more than five years old.
3. In case of imported drugs (i.e. not manufactured in India), **COPP (Certificate of Pharmaceutical Products)/ import license** and copy of the import registration of that particular molecule quoted in the tender indicating the list of products should be submitted as per WHO norms and ‘3-years’ Marketing experience certificate issued by the Drug Controller.
4. Scanned copy of **valid manufacturing license** issued by Centre/State Drug Controller indicating the list of products should be submitted. Public Sector Undertakings with at least “3-years” market standing having manufacturing license issued by Centre/ State Drug Controller.
5. Scanned copy of **valid narcotic license** issued by Central/State Excise Commissioner should be submitted by the bidder.
6. In case of newly introduced drugs/molecules, the manufacturer can be eligible provided the firm submits a certificate from the DCGI, in this regard. In such cases, the firm has to submit an MMC of the molecule concerned from the date of issue of Certificate by the DCGI of the new drug to that firm. In such case MMC of 03 years is not cleared/ completed, it will be relaxed accordingly. Also, in case of imported Drug/Formulations Form-45 (Permission Certificate) issued by DCGI will also be accepted.

In case of the newly off-patent molecules wherein MMC of 03 years is not cleared/ completed, it will be relaxed in accordance with the time from which the molecule has been declared off-patent.

In case, renewal of MMC is pending, the application for renewal will be read in continuation with the last MMC provided there is no break between the two. However, the renewed MMC will have to be provided by the firm before completion of technical evaluation; failing which the bid will summarily be rejected.

7. Firms which have **US-FDA** approval for export/selling of specified drugs in USA, may submit copies of approval documents from FDA in support of their claim.
8. Manufacturing firm should upload the scanned copy of performance certificate of 02 years for supply of drugs/medicines/iv fluids within last 05 financial years i.e. **2020-21, 2021-22, 2022-23, 2023-24 and 2024-25** from any Govt. Hospital/PSUs./reputed hospital/Institutions/International buyer on the purchaser letter head where the bidders is supplying these items in reference to this tender.
9. **Production-Capacity assessment certificate:** The manufacturing firm should enclose the certificate issued by the Chartered Accountant/ concerned State Drug Controller indicating actual production detail of a particular molecule batch wise for the items quoted and at least one

analysis batch report per year for any two of the last three years for each molecule quoted (i.e. minimum of two reports of at least **2-different years** of the last three financial years (**2022-23, 2023-24 and 2024-25**) in the enclosed Performa at **Section-XIX**.

10. Tender shall be rejected if the Copy of GST Registration Certificate is not furnished. Firm shall furnish a certificate on their letter head stating that up to date returns have been filed and there are no dues with the concerned department. Firm will also submit Scanned copies of last 01 (one) year's returns submitted to the concerned department.
11. Turnover Clause:
 - (a) Participating pharmaceutical Firms will have to submit audited financial statement by registered Chartered Accountant for last three preceding financial years (i.e. **2022-23 , 2023-24 and 2024-25**) in support of the annual turnover.
 - (b) Group turnover (other than drugs and their formulations) will not be considered for determining the eligibility and such tenders will be rejected summarily.
 - (c) The manufacturing firm quoting for the items mention below have to Submit the documents of annual turnover of the company audited by a Chartered Accountant of the pharmaceutical products during any three consecutive financial years (Financial year **2020-21, 2021-22, 2022-23 2023-24 and 2024-25**) :
 - i) Narcotic drugs, Enemas should have minimum annual turnover of Rs. 1.5 Crores.
 - Niche products/Patented Products/MSE have minimum annual turnover of Rs. 1.5 Crores.
 - ii) Cream/Ointment, lotion, eye/ear drops, mouth wash/Gargles , Contrast media, I.V fluids(large volume parenterals) should have a minimum annual turnover of Rs. 30.00 Crores.
 - iii)Tablets, Capsules, Injections should have a minimum annual turnover of at least Rs. 150.00 Crores
12. If a firm is the sole manufacturer of the product, the same can be treated as a Proprietary drug, provided the firm submits a certificate to this effect from the competent authority in India.
13. Scanned copy of **Non-conviction certificate** issued by the Centre/State Drug Controller to the effect that the manufacturer has not been convicted under the Drugs and Cosmetics Act, 1940 and rules there under during the last three years in respect of any of the drugs for which prices have been quoted by the firm. In case the DCGI does not mention the name of the molecules in their certificates, **a relevant undertaking will be provided with list of drug/molecules along with non-conviction certificate, by the vendor in addition to the above mentioned certificate.** Non-Conviction Certificate must have been issued *by the Drug Controller of the concerned State* within preceding one year from the date of the publication of the tender.
14. In case of Imported products the financial turnover of overseas manufacturing firm (Principal firm) will be considered.
15. The contractor should also give a guarantee as follows, in case of biological and other products having a particular life-period to provide safe-guard against loss on account of deterioration within their stated period of potency.
 "The seller hereby declares that the goods/store/articles sold to the buyer under this contract shall be of the best quality and shall be strictly in

accordance with the specification and particulars mentioned in the description clauses hereof and the seller hereby guarantees that the said goods/stores/articles would continue to conform to their description and quality for a period of one year from the date of delivery of the said goods/stores/articles or such portion thereof as may be discovered not to conform to the description and quality. Such rejection of the goods/articles/stores will be at the seller's risk and all the provisions herein contained relating to rejection of goods etc., or such portion thereof if rejected by the purchaser shall be applicable. Otherwise the contractor/seller shall pay to the purchaser such damages as may arise by reason of the breach of conditions herein contained. Nothing herein contained shall prejudice any other right of the purchase in that behalf under this contract or otherwise”.

16. Certificate on self attested non-judicial stamp paper of Rs.10/- stating that there is no vigilance/ CBI case pending against the firm/supplier and the firm has not been blacklisted/debarred on the date of submission of the bid by any Central Govt./State Govt. department/hospital/PSUs etc. Bidder should also provide information regarding blacklisting/debarring of the firm in last three years **(2022-23, 2023-24 and 2024-25)** by any Government or Private organization/Hospital. In case of any false information provided or concealed the information by any bidder, the bidder shall be debarred for two years and EMD/Bid Security/Performance Security submitted by the firm shall be forfeited.
17. The firms should give an undertaking to the effect that they will be legally bound to supply the medicines/drugs, for which they have quoted the rates in the tender during the validity of the contract. In case, they fail to execute any supply-order placed to them within 45 days from the date of placement of purchase order, they will be liable for action against them as per tender terms.
18. Scanned copy of Information as per the format enclosed **(Section-XVII)** should be submitted with the tender. Furnishing of false information will make the bidder ineligible and the firm will stand blacklisted.
19. Scanned copy of List of Items quoted as per **Section- XVI.**
 - a) Participating Pharmaceutical firm should submit a notarized undertaking on an affidavit of Rs. 100/- (Rupees One Hundred only) stating that:
 - i. They will comply with all the statues & legislation regarding manufacturing, import, sale and supply of drugs in India and in particular the following Acts/Enactments viz., the Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended), The Legal Metrology Act, 2009, The Drugs (Control) Act, 1950, The Indian Statistical Institute Act, 1959, GST Act.
 - ii. To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 (as amended). The bidder shall also undertake not to supply items / drugs “not of standard”, “Grossly sub-standard” and “Spurious and adulterated drugs” as per the guidelines issued by the Drug Controller of India from time to time.
 - b) The participating pharmaceutical firm should submit an affidavit of Rs. 100/- (Rupees One Hundred only) duly signed by the Notary (Annexure T) asunder:-
 - i. “The pharmaceutical firm hereby declare that the drugs/items sold to the AIIMS under this contract shall be of best quality and workmanship and shall be strictly in accordance with the specifications and particulars

contained/mentioned in the description clauses hereof and the pharmaceutical firm/bidder hereby guarantees that the said drugs/items would continue to conform to their description/ specification and the provisions of law as stated in the contract and that notwithstanding the fact that the purchaser (inspector) may have inspected and/or approved the said drugs/items. If the same be discovered not to conform to the description and quality aforesaid or have deteriorated, the decision of the AIIMS in that behalf will be final and conclusive. AIIMS will be entitled to reject said drugs/items or such portion thereof as may be discovered not to conform to the said description and quality in the manner as prescribed. Such rejection of the drugs/items will be at the seller's risk and all the provisions herein contained relating to rejection of drugs/items etc. or such portion thereof if is rejected by the purchaser. Nothing herein contained shall prejudice any other right of AIIMS in that behalf under this contract or otherwise”.

- ii. The Bidder submits stating that the drugs, which are being quoted, are not banned under Section 26 (A) of Drugs & Cosmetics Act. Or any other provision of law prevailing in India.
 - iii. It is declared that the firm / company/ corporation and any of its director / proprietors/ partners/ Authorised signatories are not convicted/ or a criminal case filed against or pending in any court of India by any department of Govt. under prevention of Corruption Act or for cheating/ defrauding Govt/ embezzlement of Govt fund or any criminal conspiracy in the said matter.
 - iv. The Bidder submits an undertaking that it is not submitting bid for any drug/ combination of drugs which is not approved by DCGI”.
 - v. Company/Authorised Signatory has to submit an affidavit giving address of Manufacturing unit.
20. For the drugs which are being imported, the Participating Pharmaceutical firm will submit valid import license issued by Drug Controller General of India and valid marketing license issued by concerned Licensing Authority (Form 10 & Form 41). That Firm will be eligible if one batch of new drug has been imported at the time of bidding.
 21. In case of patented drugs, Participating Pharmaceutical firm will submit valid certificate to this effect from the Licensing Authority else bidder's claim will not be considered.
 22. The firm / company/ corporation should not be convicted/ or a criminal case filed against or pending in any court of India by any department of Govt. under prevention of Corruption Act or for cheating/ defrauding Govt./ embezzlement of Govt. fund or any criminal conspiracy in the said matter.
 23. For the drugs quoted in the tender enquiry, Participating Pharmaceutical firm will have to submit the samples on demand. If bidder fails to submit the samples within the period specified, the tender will be rejected

Section – IX
TENDER ACCEPTANCE FORM

To _____

**The Director,
All India Institute of Medical Sciences
Ansari Nagar, New Delhi-110 029 India.**

Ref. Your ATE No. _____ due for opening on
_____ *insert date*

We, the undersigned have examined the above mentioned Tender Enquiry Document, including amendment/corrigendum (*if any*), the receipt of which is hereby confirmed. We now offer to supply and deliver in conformity with your above referred document for the sum as shown in the Price Schedules (BoQ) uploaded herewith and made part of this bid. If our bid is accepted, we undertake to supply the items for which Rate Contract has been concluded, in accordance with the delivery schedule specified in the Schedule of Requirements.

We further confirm that, if our bid is accepted, we shall provide you with a Performance Security of required amount in an acceptable form in terms of “General Conditions Contract”, Section - IV read with modification, if any “Special Conditions of Contract”, in Section - V, for due performance of the Rate Contract/Purchase Orders.

We agree to keep our bid valid for acceptance as required in the “General Instruction to Bidders”, read with modification, if any in “Special Instructions to Bidders”, Section – III or for subsequently extended period, if any, agreed to by us. We also accordingly confirm to abide by this bid up to the aforesaid period and this bid may be accepted any time before the expiry of the aforesaid period. We further confirm that, until a formal Rate Contract is executed, this bid read with your written acceptance thereof within the aforesaid period shall constitute a binding contract between us.

We further understand that you are not bound to accept the lowest or any bid you may receive against your above-referred advertised tender enquiry.

We confirm that we do not stand deregistered/banned/blacklisted by Central Govt./State Govt. Ministries/AIIMS, New Delhi.

We confirm that we fully agree to the terms and conditions specified in above mentioned Tender Enquiry Document, including amendment/ corrigendum if any.

We hereby certify that if at any time, information furnished by us is proved to be false or incorrect, we are liable for any action as deemed fit by the purchaser in addition to forfeiture of the Bid Security/Performance Security.”

Name: _____
Business Address _____

Place: _____

Date: _____

SECTION – X
PRICE SCHEDULE

BoQ may be uploaded as per instructions given in Tender Enquiry Document.

SECTION – XI
BANK GUARANTEE FORM FOR BID SECURITY

Whereas _____ (Name and address of the Bidder)
(hereinafter called the "Bidders")

has submitted its Bid dated _____ for the supply of _____
(hereinafter called the "Bid")

against the purchaser's ATE No. _____

Know all persons by these presents that we _____

having our registered office at _____
(Hereinafter called the "Bank")

are bound to AIIMS MAIN GRANT, New Delhi
(hereinafter called the "Purchaser")

in the sum of _____ for which payment will and truly to be
made to the said Purchaser, the Bank binds itself, its successors and assigns by these
presents. Sealed with the Common Seal of the said Bank this
_____ day of _____ 20_____.

The conditions of this obligation are:

- 1) If the Bidder withdraws or amends, impairs or derogates from the bid in any respect within the period of validity of this Bid.
- 2) If the Bidder having been notified of the acceptance of his Bid by the Purchaser during the period of its validity:-
 - a. If the bidder fails or refuses to furnish the performance security for the due performance of the Rate Contract/Purchase Orders or
 - b. If the bidder fails or refuses to accept/execute the Rate Contract/Purchase Orders or
 - c. If it comes to notice at any time, that the information/documents furnished in its Bid are false or incorrect or misleading or forged

We undertake to pay the Purchaser up to the above amount upon receipt of its first written demand, without the Purchaser having to substantiate its demand, provided that in its demand the Purchaser will note that the amount claimed by it is due to it owing to the occurrence of one or more the three conditions, specifying the occurred condition(s).

This guarantee will remain in force up to _____ (insert date of additional forty-five days after Bid validity) and any demand in respect thereof should reach the Bank not later than the above date.

(Signature with date of the authorized officer of the Bank)

(Name and designation of the Officer)

(Seal, name & address of the Bank and address of the Branch)

SECTION – XII
BANK GUARANTEE FORM FOR PERFORMANCE SECURITY

WHEREAS _____ (Name and address of the Supplier) (Hereinafter called “the Supplier”)

has undertaken, in pursuance of Rate Contract No. _____

dated _____ valid from _____ to _____ for supply

_____ (*insert description of goods*)
(Hereinafter called “the Contract”),

to AIIMS MAIN GRANT, New Delhi-110 029
(Hereinafter called “the Purchaser”)

AND WHEREAS it has been stipulated by you in the said contract that the supplier shall furnish you with a bank guarantee by a scheduled commercial bank recognized by you for the sum specified therein as security for compliance with its obligations in accordance with the contract;

AND WHEREAS we have agreed to give the supplier such a bank guarantee;

NOW THEREFORE we hereby affirm that we are guarantors and responsible to you, on behalf of the supplier, up to a total of

_____ (*insert Amount of the Performance Security in words and figures*), and we undertake to pay you, upon your first written demand declaring the supplier to be in default under the contract and without cavil or argument, any sum or sums within the limits of (amount of guarantee) as aforesaid, without your needing to prove or to show grounds or reasons for your demand or the sum specified therein.

We hereby waive the necessity of your demanding the said debt from the supplier before presenting us with the demand.

We further agree that no change or addition to or other modification of the terms of the contract to be performed there under or of any of the contract documents which may be made between you and the supplier shall in any way release us from any liability under this guarantee and we hereby waive notice of any such change, addition or modification.

This guarantee will remain in force up to _____ (*insert last date of currency of Rate Contract plus Warranty Period (if applicable) plus additional Ninety days*) and any demand in respect thereof should reach the Bank not later than the above date.

.....
(Signature with date of the authorized officer of the Bank)

.....
Name and designation of the officer

.....
Seal, name & address of the Bank and address of the Branch

SECTION – XIII
RATE CONTRACT FORM FOR GOODS

(To be executed on Non-Judicial Stamp Paper worth of Rs.100/-)

ALL INDIA INSTITUTE OF MEDICAL SCIENCES
(Insert Name of concerned Centre/ Hospital/ Department/ Section)
ANSARI NAGAR, NEW DELHI-110 029

Rate Contract No. _____ dated _____

To _____

(insert name of Supplier with address)

This is in continuation to this office's Notification of Award No.: _____ dated _____

1. Name & address of the Supplier: _____
2. Advertised Tender Enquiry No. of Tender Documents: _____
and subsequent Amendment No.: _____, dated: _____
(if any), issued by the Purchaser
3. Supplier's Bid No.: _____ dated: _____ and subsequent
communication(s) No.: _____ dated: _____ (if any), exchanged
between the supplier and the purchaser in connection with this Tender
Document.
4. In addition to this Rate Contract Form, the following documents etc, which
are included in the Tender Enquiry Documents mentioned under
paragraphs 2 and 3 above, shall also be deemed to form and be read and
construed as integral part of this Rate Contract:
 - i) General Conditions of Contract;
 - ii) Special Conditions of Contract;
 - iii) Schedule of Requirements;
 - iv) Technical Specifications;
 - v) Tender Acceptance Form uploaded by the supplier;
 - vi) Price Schedule(s)/BoQ uploaded by the supplier in its Bid;
 - vii) Manufacturers' Authorization Form (if applicable);
 - viii) Purchaser's Notification of Award

Note: The words and expressions used in this Rate Contract shall have the same meanings as are respectively assigned to them in the conditions of Rate Contract referred to above. Further, the definitions and abbreviations incorporated under clause 1 of Section II – "General Instructions to Bidders" of the Tender Enquiry Document shall also apply to this Rate Contract.

5. Some terms, conditions, stipulations etc. out of the above-referred documents are reproduced below for ready reference:

- i) Brief particulars of the goods which shall be supplied by the supplier against Rate Contract are as under:

Item No.	Brief Description of Goods	Unit	Unit Price (in INR)	GST Rate (in %age)	Total Unit Price with GST (in INR)

--	--	--	--	--	--

- ii) Terms of Delivery: Free Delivery At Site
- iii) Delivery schedule: 45 Days from the Date of Issue of Purchase Order
- iv) Performance Security of Rs. _____ valid upto _____ to be furnished by _____
- 6. Currency of Rate Contract from: _____ to: _____
- 7. Shelf Life: At the time of supply, the supplier will supply fresh stock, and the remaining shelf life should be more than 5/6 of shelf life.
- 8. The supplier shall arrange to effect free replacement of any quantity which may deteriorate in potency, strength etc. before the date of expiry marked on the labels.
- 9. Payment terms: As per General Conditions of Contract
- 10. The Supplier will supply the goods as per Rate Contract against Purchase Orders issued by various Centers/Hospital/Section/Departments/Store Sections of AIIMS, New Delhi.

Signature, name and designation of the Purchaser authorized official
for and on behalf of Director, AIIMS, may be called as First Party

Received and accepted this Rate Contract

Signature, name and address of the supplier's executive duly authorized to sign on behalf of the supplier, may be called as Second Party

for and on behalf of _____
(Insert Name and address of the supplier)

(Seal of the Supplier)

Date: _____

Place: _____

SECTION – XIV
CONSIGNEE RECEIPT CERTIFICATE
(To be given by consignee’s authorized representative)

The following store(s) has/have been received in good condition:

- 1) Rate Contract No. & date : _____
- 2) Purchase Order No. & date : _____
- 3) Supplier’s Name : _____
- 4) Consignee’s Name & Address: _____
- 5) Name of the item supplied : _____
- 6) Quantity Supplied : _____
- 7) Date of Receipt by the Consignee : _____

Signature of Consignee with date: _____

Name and designation of Consignee: _____

Seal of the Consignee: _____

SECTION - XV
FINAL CONSIGNEE ACCEPTANCE CERTIFICATE
(To be given by consignee's authorized representative)

- 1 This is to certify that the goods as detailed below have been received in good conditions along with all the standard and special accessories in accordance with the Rate Contract/Purchase Order and the same has been installed and accepted.
- 1) Rate Contract No. & date : _____
- 2) Purchase Order No. & date : _____
- 3) Supplier's Name: _____
- 4) Consignee's Name & Address: _____
- 5) Name of the item Supplied : _____
- 6) Quantity Supplied : _____
- 7) Date of Receipt by the Consignee : _____
- 8) Quantity Accepted : _____
- 9) Date of Acceptance by the Consignee : _____
- 10) The supplier has fulfilled its contractual obligations including installation (if applicable) satisfactorily

OR

The supplier has failed to fulfill its contractual obligations with regard to the following:

- i)
ii)
iii)
iv)
- 11) The amount of recovery on account of failure of the supplier to meet his contractual obligations is _____ (here indicate the amount).

Signature of Consignee with date: _____

Name and designation of Consignee: _____

Seal of the Consignee: _____

SECTION – XVI

LIST OF ITEMS QUOTED **FORMAT OF SUBMISSION OF VALID REVISED SCHEDULE –M/ WHO-GMP/IMPORT LICENSE/ COPP/ MANUFACTURING LICENSE (STRICT COMPLIANCE).**

Sr. No.	Item' serial no. as per tender list	Name of Drugs	Page no. Tender where valid WHO-GMP/ Revised Schedule M/ import license/ COPP/Public Sector undertakings enclosed	Page no. Tender where valid Manufacturing License/ Import license enclosed.

Strict Compliance: - All the bidders are directed to mention the page number of the tender document where WHO-GMP/ Revised Schedule 'M' & page number of manufacturing license for indigenous drugs / import license for imported drugs enclosed. Merely mentioning the word '**Enclosed**' may lead to rejection of tender / bid. Submission

- a) Participating Pharmaceutical firm should submit a notarized undertaking on an affidavit of Rs. 100/- (Rupees One Hundred only) stating that:
- They will comply with all the statues & legislation regarding manufacturing, import, sale and supply of drugs in India and in particular the following Acts/Enactments viz., the Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended), The Legal Metrology Act, 2009, The Drugs (Control) Act, 1950, The Indian Statistical Institute Act, 1959, GST Act.
 - To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 (as amended). The bidder shall also undertake not to supply items / drugs "not of standard", "Grossly sub-standard" and "Spurious and adulterated drugs" as per the guidelines issued by the Drug Controller of India from time to time.
- b) The participating pharmaceutical firm should submit an affidavit of Rs. 100/- (Rupees One Hundred only) duly signed by the Notary (Annexure T) as under:-
- "The pharmaceutical firm hereby declare that the drugs/items sold to the AIIMS under this contract shall be of best quality and workmanship and shall be strictly in accordance with the specifications and particulars contained/mentioned in the description clauses hereof and the pharmaceutical firm/bidder hereby guarantees that the said drugs/items would continue to conforms to their description/ specification and the provisions of law as stated in the contract and that notwithstanding the fact that the purchaser (inspector) may have inspected and/or approved the said drugs/items. If the same be discovered not to conform to the description and quality aforesaid or have deteriorated, the decision of the AIIMS in that behalf will be final and conclusive. AIIMS will be entitled to reject said drugs/items or such portion thereof as may be discovered not to conform to the said description and quality in the manner as prescribed. Such rejection of the drugs/items will be at the seller's risk and all the

provisions herein contained relating to rejection of drugs/items etc. or such portion thereof if is rejected by the purchaser. Nothing herein contained shall prejudice any other right of AIIMS in that behalf under this contract or otherwise”.

- ii) The Bidder submits stating that the drugs, which are being quoted, are not banned under Section 26 (A) of Drugs & Cosmetics Act. Or any other provision of law prevailing in India.
- iii) It is declared that the firm / company/ corporation and any of its director / proprietors/ partners/ Authorised signatories are not convicted/ or a criminal case filed against or pending in any court of India by any department of Govt. under prevention of Corruption Act or for cheating/ defrauding Govt/ embezzlement of Govt fund or any criminal conspiracy in the said matter.
- iv) The Bidder submits an undertaking that it is not submitting bid for any drug/ combination of drugs which is not approved by DCGI”.
- v) Company/Authorised Signatory has to submit an affidavit giving address of Manufacturing unit

SIGNATURE AND ADDRESS OF THE BIDDER

SECTION – XVII

PROFORMA TO BE FILLED BY THE TENDERER

I. GENERAL INFORMATION

- a) Name of the firm :
- b) Address & Telephone No. :
- c) Whether the firm is Indian / Multi- national :
- d) Whether Small / Medium/Large Scale Co. :
- e) Person responsible for conduct of Business :
- f) Particulars of Licenses held under Drugs & Cosmetic Act & the details. (If the license is under renewal, certificate from the Drug Controller that the license is under renewal and deemed to be enforced) :
- g) Procurement agency with which registered and the agencies to whom drugs supplied during last one year :
- h) Has the firm been convicted ever, if yes, give details:
- i) Any case pending in the Court with details:
- j) Has the firm ever been debarred / black-listed by any Govt. Hospital for poor quality or late supply of drugs? If yes, give details.
- k) Fax No :
- l) E- Mail Address :
- m) Name & Mobile No of person/ authorized signatory to be contacted for this tender :

II. TECHNICAL

- a) Equipments for material handling, manufacturing of drugs and quality-control of drugs :
- b) Specialized testing facilities such as microbiological testing and Biological testing :
- c) Details of Technical Staff
 - i) Manufacturing Staff :
 - ii) Quality Control Staff :

- d) Has the firm carried out stability study for drugs quoted :
- e) Is the firm basic manufacturer of the drug quoted, if yes, details :
- f) Has the firm following
 - i) WHO GMP Certificate /Schedule-M :
 - ii) ISO Certificate :
 - iii) FDA Certificate :
 - iv) Import License :
- g) Installed capacity and actual production details for different forms of drugs :
 - i) Tablets :
 - ii) Capsules :
 - iii) Syrups/ Suspension :
 - iv) Injections :
 - v) Powder :
 - vi) Inhalation :
 - vii) Topical :
- h) Drugs declared and sub-standard / re-called during the last three years.
Give details with reasons and the remedial action taken :

III. FINANCIAL

- a) Turnover during last three financial years (year wise) of the pharmaceutical products. Firms should furnish copies of audited Balance-sheet / Sales Tax clearance certificate.
- b) Name & Address of the Bankers to the Firm and the facilities available from the bank.
- c) Income-tax No./ Central Sales-tax No./ State Sales-tax No.

DECLARATION

I, _____ Proprietor/Partner/Director of M/s _____ hereby declare that the information given in this form is true and correct to the best of my knowledge and belief.

(Signature)

(Name & Designation with Stamp)

WARNING: If the information furnished in this form is found to be incorrect at any point of time, the bidder may be debarred.

SECTION – XVIII

MANUFACTURING & MARKETING CERTIFICATE

This is to certify that M/s _____ are holding valid Manufacturing license No. _____ dated _____ of the _____ State and they are manufacturing and marketing, the following products for last three (3) years.

The products are as follows:

S. No.	Name of the Product	Pharmacopoeia Specification	Strength
1.			
2.			
3.			
4.			
5.			
6.			
7.			
8.			
9.			
10.			

**Signature and seal of
Drug Controller of
the Centre/State.**

Dated:

Note: This certificate is to be signed by the Drug Controller of **Centre/State**. Certificate issued by Inspector of Drugs will not be accepted unless an authorization by the concerned centre/State Drug Controller to this effect is supported by adequate documentary proof.

SECTION – XIX

PRODUCTION-CAPACITY ASSESSMENT CERTIFICATE

Item no. & name of items:_____

Indicate details of production of the items quoted at least two years from **2022-23**
2023-24 and **2024-25** duly certified by the **Chartered Accountant/ Centre/State Drug**
Controller.

S. No. of the item as in Tender Enquiry	Name & Specification of the item	Date of issue of Mfg. License for the product	Date of marketing the 1st batch
1.	2.	3.	4.

2022-23		2023-24		2024-25		REMARKS
Batch No.	Size	Batch No.	Size	Batch No.	Size	

Signature of the Manufacturer:

**Signature of the Chartered Accountant/
Centre/State Drug Controller along with address & Seal**

SECTION – XX
CHECKLIST

Sr. No.	Documents to be submitted alongwith the techno-commercial bid	Attached at page number
a.	Scanned copy of “EMD/Bid Security” furnished in accordance with GIB alternatively, documentary evidence as per GIT for claiming exemption from payment of EMD/Bid security to be uploaded.	
b.	Scanned copy of “List of Items Quoted” as per SECTION – XVI of Tender Enquiry Document.	
c.	Scanned copy of “Tender Acceptance Form” as per Section IX to be uploaded	
d.	Scanned Copy of GST Registration Certificate. Copy of GST No dues Certificate Scanned copies of last 2 year’s GST returns submitted to the concerned department	
e.	Scanned copy of Documents confirming to Sole Proprietorship/ Partnership/Private Limited Firm in the country of origin as the case may be to be uploaded.	
f.	Scanned copy of Manufacturing & Market standing/ experience certificate of minimum “Three Years” of the molecule quoted by them duly certified by centre/ State Drug Controller in the Performa Section- XVIII . The certificate should have been issued recently i.e. not more than one year old from the date of the opening of the tender.	
g.	Scanned Copy of Valid WHO-GMP certificate/ Valid Schedule ‘M’ certificate clearly indicating the products (molecule/drug) issued by Centre/ State Drug Controller and should not have been issued more than five years old.	
h.	In case of imported drugs (i.e. not manufactured in India), COPP (Certificate of Pharmaceutical Products)/ import license and copy of the import registration of that particular molecule quoted in the tender indicating the list of products should be submitted as per WHO norms and ‘3-years’ Marketing experience certificate issued by the Drug Controller. In case of the newly off-patent molecules wherein MMC of 03 years is not cleared/ completed, it will be relaxed in accordance with the time from which the molecule has been declared off-patent. In case, renewal of MMC is pending, the application for renewal will be read in continuation with the last MMC provided there is no break between the two. However, the renewed MMC will have to be provided by the firm before completion of technical evaluation; failing which the bid will summarily be rejected.	
i.	Scanned copy of valid manufacturing license issued by Centre/State Drug Controller indicating the list of products should be submitted. Public Sector Undertakings with at least “3-years” market standing having manufacturing license issued by Centre/ State Drug Controller.	

j.	In case of newly introduced drugs/molecules, the manufacturer can be eligible provided the firm submits a certificate from the DCGI, in this regard. In such cases, the firm has to submit an MMC of the molecule concerned from the date of issue of Certificate by the DCGI of the new drug to that firm. In such case MMC of 03 years is not cleared/ completed, it will be relaxed accordingly.	
k.	Manufacturing firms should submit scanned copy of performance certificate(s) of at least 02 years in last 05 years (2020-21, 2021-22, 2022-23, 2023-24 and 2024-25) , from other similar two Hospital, out of which one must be from Government/Public Sector from the Competent Authority.	
l.	Production-Capacity assessment certificate as per section-XIX	
m.	<p>Turnover:</p> <p>(a) Participating pharmaceutical Firms will have to submit audited financial statement by registered Chartered Accountant for last three preceding financial years (i.e.2022-23, 2023-24 and 2024-25) in support of the annual turnover.</p> <p>(b) Group turnover (other than drugs and their formulations) will not be considered for determining the eligibility and such tenders will be rejected summarily.</p> <p>(c) The manufacturing firm quoting for the items mention below have to Submit the documents of annual turnover of the company audited by a Chartered Accountant of the pharmaceutical products during any three consecutive financial years (Financial year 2020-21, 2021-22, 2022-23, 2023-24 and 2024-25) :</p> <p>i) Narcotic drugs, Enemas should have minimum annual turnover of Rs. 1.5 Crores.</p> <p>Niche products/Patented Products/MSE have minimum annual turnover of Rs. 1.5 Crores.</p> <p>ii) Cream/Ointment, lotion, eye/ear drops, mouth wash/Gargles , Contrast media, I.V fluids(large volume parenterals) should have a minimum annual turnover of Rs. 30.00 Crores.</p> <p>iii)Tablets, Capsules, Injections should have a minimum annual turnover of at least Rs. 150.00 Crore</p>	
n.	Scanned copy of Non-conviction certificate	
o.	Certificate on self attested non-judicial stamp paper of Rs.10/- stating that there is no vigilance/ CBI case pending against the firm/supplier and the firm has not been blacklisted/debarred on the date of submission of the bid by any Central Govt./State Govt. department/hospital/PSUs etc. Bidder should also provide information regarding blacklisting/debarring of the firm in last three years (2022-23, 2023-24 and 2024-25) by any Government or Private organization/Hospital. In case of any false information provided or concealed the information by any bidder, the bidder shall be debarred for two years and EMD/Bid Security/Performance Security submitted by the firm shall be forfeited.	

p.	The firms should give an undertaking to the effect that they will be legally bound to supply the medicines/drugs, for which they have quoted the rates in the tender during the validity of the contract. In case, they fail to execute any supply-order placed to them within 45 days from the date of placement of purchase order, they will be liable for action against them as per tender terms.	
q.	Scanned copy of Information as per the format enclosed (Section-XVII) should be submitted with the tender. Furnishing of false information will make the bidder ineligible and the firm will stand blacklisted.	
r.	At least one analysis batch report per year for any two of the last three years for each molecule quoted (i.e. minimum of two reports of at least 2-different years of the last three financial years (2022-23, 2023-24 and 2024-25) in the enclosed Performa at Section-XIX .	
s.	Name and address of the authorized distributor for supplying against the subject tender along with the OEM authorization certificate to be uploaded.	

ANNEXURE
List of Drugs/Medicines

ANNEXURE		
S.no.	Item Name	Annual Consumption
1	Solution Cardioplegia Solution 1000 ML, M mol/L NaCl 15, KCL 9, Mg SO ₄ 6 H ₂ O ₄ , Histidine HCl H ₂ O ₁₈ , HISTIDINE 180, TRYPTOPHAN 2, MANNITOL 30, Ca Cl ₂ 2 H ₂ O 0.15, K, H, 2 KETOGLUTA 1, RATE OSMOLARITY 310 MOSMOL/ 1000 ml Solution 1000 ml	5000
2	Tab Simvastatin 10mg	50000
3	Tab Simvastatin 20mg	15000
4	Tab Terazosin 1mg	40000
5	Tab. Hydrochlorthiazide 12.5mg	30000
6	Tab. Hydrochlorthiazide 25 mg	40000
7	Powder for injection hydralazine 20 mg (hydrochloride) in ampoule.	1000
8	Injection verapamil 2.5 mg/mL (hydrochloride) in 2 mL ampoule	6000
9	Inj. Nicardipine (1mg/ml)	6000
10	Tablet amiloride 5 mg (hydrochloride).	80000
11	Tablet bisoprolol 1.25 mg	20000
12	Solid oral dosage form hydralazine 25 mg(hydrochloride)	20000
13	Solid oral dosage form hydralazine 50 mg (hydrochloride)	20000
14	Syrup Furosemide 10 mg/mL	4000
15	Syrup Spironolactone 5 mg/5 mL	1000
16	Syrup Spironolactone 25 mg/5 mL	1000
17	Capsule Phenoxybenzamine 10mg	2500
18	Tablet S-Atenolol + Hydrochlorothiazide 25mg + 12.5mg	15000
19	Capsule Atorvastatin + Aspirin 20mg + 75mg	2000
20	Tablet Clonidine 0.2 mg	36000
21	Syrup Digoxin 3mg / 5ml (60ml)	2500
22	Injection Diltiazem 25mg 5ml	3500
23	Tablet Dipyridamole 100mg	15000
24	Syrup Furosemide 60ml (10mg /ml)	5000
25	Tablet Furosemide 40mg	60000
26	Tablet Ivabradine 2.5mg	1200
27	Tablet Labetalol 50mg	27000
28	Injection Levosimendan 12.5mg / 5ml vial	300
29	Injection Mephentermine 15 mg 1ml	18000
30	Tablet Methyl Dopa 250 mg	5000
31	Tablet Minoxidil 5mg	2000
32	Spray Nitroglycerin 400 mcg / spray	500
33	Injection Papaverin 60mg / 2ml	700

34	Injection Phenoxy Benzamine HCL 50mg 1ml Amp	2000
35	Solution Cardioplegia solution 1ML , KCl - 59.55 MG , Mg Cl2-162.65 mg Procaine HCL 13.64 mg 20 ml	700
36	Tablet Prasugrel 5 mg	10000
37	Tablet Propafenone 150mg	15000
38	Tablet S-Atenolol 12.5mg	20000
39	Tablet Sildenafil 25mg	4800
40	Tablet Simvastatin 5mg	20000
41	Tablet Simvastatin 20mg	20000
42	Tablet Sotalol 20 mg	5000
43	Injection Streptokinase 15,00,000 IU / ml	600
44	Injection Streptokinase 7,50,000 IU / ml	500
45	Tablet Tadalafil 40mg	5000
46	Tablet Terazosin 5 mg	10000
47	Tablet Triamterene + Benzthiazide 50mg + 25mg	15000
48	Sachet Calcium Polystyrene Sulphonate 15g	15000
49	Tablet Prazosin 1mg	15000
50	Tablet Minoxidil 2.5 mg	10000
51	Tablet Furosemide 100 mg	20000
52	Syrup Furosemide 300mg 30ml	5000
53	Injection Centhaquine citrate 1 mg	10000
54	Syrup Furosemide + Spironolactone 10mg / ml	15000
55	Tablet Midodrine 10mg	15000
56	Tablet Atorvastatin + Aspirin 20mg + 75mg	2000
57	Injection Lignocaine Hcl (Preservative free) 21.3mg / ml 2% (30 ml)	10000
58	Injection Piracetam 400mg	10000
59	Tab Bupropion sustained – release 150 mg	20000
60	Tab. Lithium Carbonate 300mg	5000
61	Inj. Ropivacaine 0.50% 10ml	2500
62	Tab. Nitrazepam 5 mg	500000
63	I.V. / I.M. Inj. Prochlorperazine 12.5 mg / ml	1000
64	Tablet biperiden 2 mg (hydrochloride)	20000
65	Tablet Clomipramine 75 mg	10000
66	Tablet codeine 30 mg (phosphate)	20000
67	Tablet ethosuximide Capsule 250 mg	6000
68	Tablet MR Levodopa 100 mg + Carbidopa 25 mg	10000
69	Tablet MR Levodopa 200 mg + Carbidopa 50 mg	10000
70	Tablet Levodopa 250 mg + Carbidopa 25 mg	10000
71	Tablet Sumatriptan 25 mg	10000
72	Dental cartridge lidocaine + epinephrine (adrenaline) 2% (hydrochloride) + epinephrine 1:80 000	20000
73	Syrup Carbamazepine 100 mg / 5 mL	1000
74	Syrup Chlorpromazine 25 mg / 5 mL (hydrochloride)	500
75	Syrup Diazepam 2 mg / 5 mL	1000

76	Syrup Haloperidol 2 mg / 5 mL	2000
77	Syrup Methadone 10 mg / mL	500
78	Syrup Midazolam 2 mg / mL	2000
79	Morphine sulfate Granules 20 mg	1000
80	Syrup Phenobarbital 15 mg / 5 mL	2000
81	Tablet Feropenem 200mg	1500
82	Injection Chloroprocaine 0.01	250
83	Injection Halothane 250ml	250
84	Syrup Chloral Hydrate 500 mg/5ml	20000
85	Tablet Chlorpromazine 100mg	10000
86	Injection Chlorpromazine 25 mg/ml (2 ml amp)	2000
87	Injection Fluphenazine decanoate Depot 25mg / ml	500
88	Tablet Haloperidol 2.5 mg.	20000
89	Injection Haloperidol 5mg 1ml	5000
90	Injection Haloperidol decanoate Depot 50mg / ml	5000
91	Tablet Lamotrigine 5mg	10000
92	Tablet Lithium Carbonate SR 150mg	30000
93	Injection Lorazepam 4 mg / ml	5000
94	Injection Lorazepam 2mg 1ml	2000
95	Tablet Olanzapine + fluoxetine 5mg + 20mg	30000
96	Syrup Oxcarbazepine 5ml / 300mg	1100
97	Syrup Phenytoin Sodium 25mg / ml (100ml)	1200
98	Injection Phenytoin Sodium 100mg 2ml	20000
99	Tablet Pregabalin 300mg	10000
100	Injection Prochlorperazine 12.5mg	500
101	Tablet Pyritinol 200mg	5000
102	Suspension Pyritinol 200mg	500
103	Syrup Sodium Valproate 200mg / 5ml	600
104	Syrup Triclofos 500mg / 5ml (30ml)	2000
105	Tablet Trifluoperazine 5mg	20000
106	Tablet Vigabatrin 500mg	10000
107	Tablet Zaleplon 5mg	20000
108	Intracavernosal Injection Chlorpromazine 50mg	1000
109	Tablet Methyl Phenidate 10mg	15000
110	Tablet Methyl Phenidate 20mg	5000
111	Tablet Atomoxetine 10mg	800
112	Syrup Ethosuximide 250mg / 5ml	450
113	Syrup Respridone 1mg / 1ml	300
114	Injection Olanzapine 10mg / vial	3000
115	Syrup Phenytoin Sodium 30mg / 5ml	1000
116	Inj. Serplulimab 100mg vial	300
117	Tablet Dicyclomine + Chlordiazepoxide + cinitidum bromide (10mg + 5mg + 2.5mg)	1000
118	Tablet Midazolam 7.5mg	5000
119	Spray Midazolam 0.5mg / 0.1ml	800

120	Nasal Spray Midazolam 5mg	1000
121	Patch Rivastigma Patch 5 mg	100
122	Patch Rivastigma Patch 10 mg	100
123	Liquid Pheniramine Maleate with Ammonium Chloride & Menthol 15mg / ml (100ml)	5000
124	Syrup Promethazine Hydrochloride + Pholcodine 1.5mg + 1.5mg (60ml)	2000
125	Tablet Bromocriptine 2.5mg	5000
126	Tablet Bromocriptine 5 mg	5000
127	Tablet Paracetamol + Caffiene 650mg + 50mg	10000
128	Tablet Chlorzoxazone + Paracetamol + Diclofenac 250mg + 325mg + 50mg	100000
129	Oint Piroxicam 30gm (0.5%w / w)	1500
130	Cap. Ampicillin 250 mg + Cloxacillin 250mg 500 mg	10000
131	Tab. Ketorolac 10mg	10000
132	Syp. Cefixime 300mg 30ml	5000
133	Inj. Ampicillin 500 mg	5000
134	Tab. Roxythromycin 150mg	15000
135	Syrup Cefuroxime 125mg / 5ml (30ml)	2000
136	Cap. Dextropropoxyphene (Plain) 65mg	1000
137	Oily suspension for injection chloramphenicol 0.5 g / mL (as sodium succinate) in 2 mL ampoule	1000
138	Solution for injection ibuprofen 5 mg/mL	3000
139	Powder for injection Benzylpenicillin 5 lac units	500
140	Powder for injection Actinomycin D 0.5 mg	1000
141	Powder for injection Amoxicillin 500 mg	4000
142	Capsule Clindamycin 50 mg	10000
143	Tablet cefalexin 250 mg	10000
144	Tablet Phenoxymethyl penicillin 250 mg	10000
145	Tablet Naproxen 250 mg	20000
146	Suppository acetylsalicylic acid 50 mg to 150 mg	6000
147	Suppository paracetamol 100 mg	6000
148	Transdermal Diclofenac Patches 100	20000
149	Transdermal Diclofenac Patches 200	20000
150	Syrup Acetylcysteine 10%	2000
151	Syrup Amoxicillin 125 mg / 5 mL	3000
152	Syrup Amoxicillin 250 mg / 5 mL	3000
153	Syrup Cefalexin 125 mg / 5 ml	1000
154	Syrup Cefalexin 250 mg / 5 mL (anhydrous)	1000
155	Syrup Chloramphenicol 150 mg / 5 mL (as palmitate)	200
156	Syrup Ciprofloxacin 250 mg / 5 mL (anhydrous)	500
157	Syrup Clarithromycin 125 mg / 5 mL	500
158	Syrup Cloxacillin 125 mg / 5 mL	500
159	Syrup Doxycycline 50 mg / 5 mL	500

160	Powder for oral liquid Linezolid 100 mg / 5 mL	1000
161	Syrup Phenoxymethylpenicillin Powder for oral liquid: 250 mg / 5 mL (as potassium)	1000
162	Injection Lincomycin Hydrochloride 300mg / ml	800
163	Injection Benzathine Penicillin 600,000 units	800
164	Injection Benzathine Penicillin 1,200,000 units	750
165	Injection Cefazoline 1gm	6000
166	Injection Chloramphenicol 1 gm	600
167	Injection Cloxacillin 500 mg	600
168	Two Port Close system container Levofloxacin 100ml	4300
169	Two Port Close system container Ofloxacin 100ml	3000
170	Liquid Ofloxacin 300mg 30ml	2000
171	Injection Streptomycin 0.75mg	1000
172	Injection Cyclosporine 50mg / ml (250mg)	1000
173	Suspension Amoxicillin + Clavulanic acid (250mg+ 62.5 mg)	1200
174	Syrup Amoxycillin 750mg (30 ml)	2000
175	Tablet Cefaclor 500mg	1500
176	Tablet Cefaclor 250mg	1200
177	Liquid Cefadroxil 750mg (30 ml)	1000
178	Capsule Cefadroxil 500mg	1100
179	Tab Cefadroxil 125mg	2000
180	Syrup Ciprofloxacin 2mg (60ml)	2200
181	Capsule Cloxacillin 500 mg	1100
182	Syrup Linezolid 10mg / 5ml	500
183	Tablet Nalidixic acid 250mg	2000
184	Tablet Nalidixic acid 500mg	2000
185	Tablet Norfloxacin 400mg	5500
186	Tablet Norfloxacin 200mg	1200
187	Tablet Norfloxacin 100mg	1100
188	Injection Cefpirome 500mg	700
189	Patch Fentanyl 75 mcg / hr release	3800
190	Tablet Ibuprofen + codeine phosphate 200mg + 12.8mg	2000
191	Suppository Paracetamol 125mg	2320
192	Injection Indomethacin 1mg	1000
193	Syrup Ibuprofen 1500mg 60ml	500
194	Syrup Ibuprofen + Paracetamol 100mg + 125mg 60ml	2660
195	Tablet Indomethacin 50mg	1000
196	Patch Diclofenac 100mg	700
197	Tablet Aceclofenac + Rabeprazole 200mg + 20mg	6000
198	Injection Piroxicam 40mg 2ml	800
199	Tablet Paracetamol + Caffeine 500mg + 25mg	10000
200	Tablet Cotrimoxazole (Sulphamethoxazole + Trimethoprim) 800mg + 160mg	1000

201	Syrup Cotrimoxazole (Sulphamethoxazole + Trimethoprim) 200mg + 40mg	1000
202	Injection Pegaptanib sodium 0.3mg / 90uL	800
203	Capsule Indomethacin 50mg	5000
204	Tablet Diacerin 50mg	40000
205	Tablet Trimethoprim 200mg	5000
206	Syrup Nitrofurantoin 25mg / 5ml	500
207	Tablet Norfloxacin + Tinidazole 400mg + 600mg	50000
208	Tablet Glycopyrrolate 0.5mg	50000
209	Tablet Pantoprazole 20mg	As & when Required
210	Suspension Oxetacaine , Al(OH) ₃ , Mg(OH) ₂ 10mg + 291mg + 98mg (200 ml)	100000
211	suppository Bisacodyl 10mg	20000
212	Foam enema for topical therapy Hydrocortisone rectal foam enema 10% w/v	1000
213	Tab. Ciprofloxacin + Tinidazole 500mg + 600mg	60000
214	Syp. Domperidone Suspension 1mg 30ml	1500
215	Tab. Combination of Al. Hydroxide Magnesium hydroxide / trisilicate . Simethicone , Activated methyl polysilox etc 100mg	3000
216	Inj. Hyoscine Butyl Bromide 20mg 1ml amp	1000
217	Injection sodium nitrite 30 mg / mL in 10 mL ampoule.	500
218	Injection Hydroxocobalamin 1 mg / mL	20000
219	Tablet 5 - aminosalicylic acid (Mesalazine/ Mesalaine) 400mg	60000
220	Tablet Dicyclomine 0.25mg	30000
221	Modified Release Tablet Diethylcarbamazine (DEC) 180mg	10000
222	Tablet diloxanide 500mg (furoate)	10000
223	Capsule docusate sodium 100mg	60000
224	Tablet ivermectin 3mg	40000
225	Tablet Mebendazole 100mg	20000
226	Tablet Loperamide 4mg	30000
227	Suspension for intratracheal instillation surfactant 80 mg/ML 3 ML	500
228	Syrup Dicyclomine 10 mg / 5mL	1000
229	Syrup Diethylcarbamazine (DEC) 120 mg / 5 mL	500
230	Syrup Docusate Sodium 50 mg / 5 mL	1000
231	Syrup Mebendazole 100 mg / 5 mL	500
232	Syrup Mefenamic acid 100 mg / 5 mL	500
233	Syrup Nystatin 50 mg / 5 mL	500
234	Syrup Nystatin 100 000 IU / mL	500
235	Powder for oral liquid Omeprazole 20 mg	2000
236	Syrup Pyrantel 50 mg / mL (as embonate or pamoate)	500
237	Oral liquid Nitazoxanide 100 mg / 5 ml	500
238	Powder Ispaghula Husk & Lactulose 3.5gm + 10gm (80-100gm)	20140

239	Suppository for topical therapy Mesalamine suppository 1gm	500
240	Syrup Ofloxacin + Ornidazole 50mg + 125mg	500
241	Tablet Ciproflaxcin + Ornidazole 500mg + 500mg	2100
242	Tablet Itopride 50mg	800
243	Tablet Ivermectin 6mg	6500
244	Tablet Ivermectin 12mg	6500
245	Syrup Sucralfate 1000mg / 10ml (150ml-200ml)	1381
246	Tablet Mesalamine 400 mg	20000
247	Suspension Metronidazole + Norfloxacin 100mg + 100mg	1000
248	Tablet MILTEFOSINE 50MG	1000
249	Tablet MILTEFOSINE 100MG	1000
250	Cap. Niraparib 100mg	200
251	Injection SODIUM STIBOGLUCONATE 100MG	700
252	Capsule Miltefosine 50mg	1000
253	Tablet Sodium Bicarbonate 500mg	4000
254	Syrup Ursodeoxycholic Acid 250mg	500
255	Tablet Trypsin / Chymotrypsin 2,00,000 AU	5000
256	Sachet Prebiotic & Probiotic 1gm	10000
257	Injection 2-cyanoacrylate 0.25ml	500
258	suppository Bisacodyl 5mg	20000
259	Tube Combination of Corticosteriods containing beclomethasone and lignocaine /Or Antibiotic and /or other ingredients Rectal prep 20gm (0.25% w/w + 2.5% w/w)	600
260	Capsule Simethicone 140mg	8000
261	Tablet Charcoal 200 mg	40000
262	Tablet Hyoscine Butyl Bromide 10mg	5000
263	Powder Ispaghula husk SF (80-100gm)	2000
264	Capsule Lactic Acid Bacillus 120 million spores	30000
265	Sachet Lactic Acid Bacillus 1.25 billion cells (1gm)	30000
266	Sachet Lactic Acid Bacillus 150 million cells	30000
267	Tablet Bisacodyl 5mg	1000
268	Injection Sodium Bicarbonate 100 ml	30000
269	Suppository Glycerol Suppository (paeds and adults) 2gm	1000
270	Syrup Dicyclomine + Dimethicone 60 ml	1000
271	Injection Drotaverine 80mg	3595
272	Injection SODIUM STIBOGLUCONATE 100MG	700
273	Injection Ethamsylate 250mg 2ml	1500
274	Tablet Fenofibrate 200mg	5000
275	Injection Flumazenil 1 mg	1000
276	Injection Naloxone 1 mg	1500
277	Injection BAL (Dimercaprol) 100mg / vial	200
278	spray Dimethicone 1.30%	500
279	Tablet Dicyclomine + Meptenoic Acid 10mg + 250mg 10mg + 250mg	5000

280	Tablet Praziquantel 600mg	1000
281	Tablet Pantoprazole 20mg	1000
282	Injection Pneumococcal Polysaccharide conjugate vaccine (23 Serotype) 25 mcg 0.5ml	1000
283	Injection Quadrivalent Influenza Vaccine 0.25 PFS	30000
284	Injection Varicella Zoster Immunoglobulin 250units	20000
285	Injection Ferric carboxymaltose 750mg	10000
286	Oral Vaccine Rotavirus vaccine (live attenuated, oral) 1.5ml	1000
287	IV Folic acid, cyanocobalamin, and NICOTINAMIDE 10 ML VIAL	4000
288	Tablet Phytomenadione (Vitamin K1) 10 mg	20000
289	Injection Hemophilus Influenza B conjugated vaccine 1ml 10mcg	450
290	Injection Inactivated trivalent Influenza vaccine multidose vial	150
291	Injection Purified Protein derivated 5TU 0.1ml	400
292	Injection Corona Vaccine	20000
293	Injection Bivalent Cervical CA Vaccine strains 16 & 18 Strain 16-20mcg , strain 18- 20mcg	350
294	Injection Anti Gas Gangrene Serum 30000 IU	350
295	Injection Anti-Human 1-Lymphocyte Immunoglobulin 100 IU	400
296	Injection Tetanus Anti-toxin 20,000IU / 5ml vial	500
297	Injection Oral Polio Vaccine 10ml	500
298	Capsule Oral Typhoid Vaccine Live oral Ty21a	1000
299	Injection DPT , Hepatitis B & HIV Combination	450
300	Injection Human Papillomavirus vaccine (Bivalent)	500
301	Injections Gangrene Antitoxin (Globulins) 10000 IU / ml. amp	400
302	Syrup Zinc dry powder for suspension 5.25g / 15ml	500
303	Tablet Biotin, zinc oxide, L-methionine and L- cystine	15000
304	Capsule Beta-carotene, Copper, manganese, Selenium, and Zinc sulphate. 10Mg + 27.5mg + 70mg + 2mg + 1mg	10000
305	Capsule Antioxidant Vitamins Beta Carotenoids with Vit. A, C, E	60000
306	Powder Collagen peptides Sachet 10 gm	5000
307	Injection DOCOSAHEXANOIC ACID + EICOSAPENTAENOIC ACID 1.44GM + 1.25GM	500
308	Syrup Carnitine 500 / 5ml	200
309	Tablet Carnitine 500mg	500
310	Capsule CetylMyristoleate + EPA + DHA 20.5mg +13.5mg + 9.5mg	10700
311	Inj. Tirzepatide 2.5mg	200
312	Inj. Tirzepatide 5mg	200
313	Tablet Combination of Calcium Carbonate 1250mg eq. to Elemental Calcium (500mg) + Vitamin D3 (500IU) + Vitamin B12 (15mcg) 1250mg + 500mg + 500IU + 15mcg	24000

314	Tablet Combination of Calcium Citrate 1000 mg + Mag. Hydroxide Zinc Sulp. + Vitamin D3 1000mg	15000
315	Injection Dextranomer + Hyaluronic acid 50mg +15mg (1ml)	400073
316	Tablet Elemental Calcium carbonate with Cholecalciferol 500 mg + 400IU	45000
317	Injection Erythropoietin Beta 3000IU Pfs	1000
318	Injection Folic Acid + Vit B12 + Niacinamide + Vitamin C 0.7mg + 2500mcg + 12mg + 150mg	1500
319	Injection Levocarnitine 1gm	1000
320	Tablet L-methylfolate 2.5 mg	10000
321	Drops Oral preparations containing Ferrous sulphate / Ferrous fumarate / Ferrous gluconate / Ferrous ammonium citrate Elemental iron 100mg	3000
322	Injection Recombinant Human Erythropoietin Cartridge 30000IU	500
323	Tablet Resendronate 35mg	As & when Required
324	Tablet Methylcobalamin + Vitamin B6 (Pyridoxine) + Folic Acid 1500mcg + 20mg + 5mg	5000
325	Capsule Vitamin A 25000IU	1000
326	Tablet Biotin 3mg	10000
327	Drop D-Alpha Tocopherol 50mg/ml	1000
328	Syp Vit A 100000 IU 50ml	2000
329	Tablet Pyridoxal Phosphate 25mg	20000
330	Tablet Pyridoxine 40mg	6000
331	Tablet Riboflavin 5mg	20000
332	Injection Vit A 50000 IU 2ml	1000
333	Injection Vit B-12 1000 mcg / ml	1000
334	Capsule VitA 50000 IU	30000
335	Tablet Vitamin K 5mg	1400
336	Tablet Pancreatic Enzyme 8 mg	5000
337	Tablet Zinc acetate 25	8000
338	Intra-Vitreal Injection Aflibercept 2mg / 0.05ml	1000
339	Eye Drop Brimonidine Tartrate 0.15% w/v (5ml)	5000
340	Eye Drop Ciprofloxacin 0.3% 5ml	5000
341	Eye Drop Homatropine Hydrobromide 2% 10ml	5000
342	Eye Drop Pilocarpine 2% 5ml	5000
343	Eye Drop Sodium Chloride 0.05	5000
344	Eye Drop Voriconazole 1%	5000
345	Eye Drop carboxymethylcellulose 0.5% + stabilized oxychloro complex 0.01% with glycerine erythritol levocarnitine mgcl + sodium citrate dihydrate 10ml 0.5% / 10ml	5000
346	Eye Drop Brimonidine tartrate + timolol maleate + BAK 0.02% + 0.5% + 0.005%	5000
347	Ophthalmic Visco surgical Device 1.4% Sodium Hyalurate 14mg / ml Full Sizes 0.55ml - 0.85ml Viscosity 300,000m Pas	5000

348	Injection Sodium Fluoresin 20% 3ml	5000
349	Injection Visvolastic (Sodium Chondroitin Sulphate+ Sodium Hyaluronate) 0.75ml (40mg + 30mg)	5000
350	Ear Drop Clotrimazole	1000
351	Solution (eye drops) Azithromycin 1.5%	200
352	Solution (eye drops) tetracaine 0.5% (hydrochloride)	400
353	Eye ointment Atropine 1% 3gm	3549
354	Eye ointment Acyclovir 3%w/v (5gm)	34700
355	Eye Drop Atropine + Chloramphenicol + Dexamethasone 1% + 0.5% + 0.1%	100
356	Eye Drop Betamethasone Sodium Phosphate + Neomycin Sulphate 0.1% + 0.5%	1200
357	Eye Drop Betaxolol 0.50%	500
358	Eye Drop Betaxolol 0.25%	600
359	Eye Drop Diclofenac 0.1% w/v 5ml	180200
360	Eye Drop Phenylephrine 5% 5ml	800
361	Eye Drop Gentamycin 0.3% 5ml	6320
362	Eye Drop Norfloxacin 0.3% 5ml	700
363	Eye Drop Pilocarpine 4% 5ml	1000
364	Eye ointment Polymyxin B + Chloramphenicol + Dexamethasone 100000 IU+ 10mg +1mg(5gm)	670
365	Eye ointment Ciprofloxacin 10gm 0.3% w/w	1000
366	Intavenous Injection Lyophilized Indocyanine green Dye 25mg	2000
367	Intra Corneal Carbachol 0.01% w/v	500
368	Ophthalmic Visco surgical Device 1% Sodium Hyalurate latex free 10mg / ml Full Sizes 0.55ml - 0.85ml. Viscosity 300,000mPas	1200
369	Ophthalmic Viscosurgical Device 2.3% Sodium Hyalurate 23mg / ml Full Sizes 0.50ml - 0.60ml Viscosity 700,000mPas	800
370	Injection Sodium hyaluronate 23mg / ml	700
371	Injection Pilocarpine 1ml 0.005	3000
372	Injection Verteprofin Powder Visudyne 15 mg	600
373	Hydroxypropyl Methylcellulose Drops	10000
374	Sodium Hyaluronate 0.1 % Drops	10000
375	Drops Sodium Hyaluronate 0.15 % + Polyethylene Glycol 400 (0.4 % + Propylene Glycol 0.3 %)	10000
376	Propylene Glycol 0.6 % Drops	10000
377	Syrup Guaiphenesin + Dextromethorphan + Chlorpheniramine maleate Sugar free 50ml	25000
378	Syrup Guaiphenesin + Dextromethorphan H Br + Chlorpheniramine Mal. Syrup base 100mg + 10mg + 4mg (100ml)	25000
379	Tablet. Salbutamol + theophylline 2mg + 100mg	50000
380	Respules Salbutamol Respiratory Solution 1mg / ml (2.5ml)	50000
381	Injection Surfactant 80mg / ml (1.5ml)	10000
382	Inhaler MDI Formoterol + Glycopyrronium 9mcg / 4.8mcg	10000

383	Inhaler Formeterol + budesonide 4.5mcg + 160mcg	2000
384	Syp. Codeine phosphate + Chlorpheniramine Maleate 10mg + 4mg (100ml)	500
385	Injection cyclizine 50 mg / mL	2000
386	Inj. Emeticumab 150mg / 1ml	100
387	Tablet cyclizine 50 mg	10000
388	Tablet Ethambutol 600 mg	30000
389	Tablet Ethionamide Tablet 125 mg	30000
390	Tablet (scored) isoniazid + pyridoxine + sulfamethoxazole + trimethoprim 300 mg + 25 mg + 800 mg + 160 mg	20000
391	Tablet isoniazid + rifampicin 75 mg + 150 mg	30000
392	Tablet isoniazid + rifampicin 150 mg + 300 mg	30000
393	Tablet isoniazid + rifapentine : 300 mg + 300 mg	30000
394	Dispersible Tablet Montelukast 4 mg	30000
395	Syrup Ethambutol 25 mg / mL	500
396	Syrup Isoniazid 50 mg / 5 mL	1000
397	Syrup Loratadine 1 mg / mL	500
398	Syrup Pyrazinamide 30 mg / mL	1000
399	Syrup Rifampicin 20 mg / mL	1000
400	Syrup Cefdinir 750mg (30 ml)	800
401	Liquid Diphenhydramine + Ammonium Chloride + Sodium Citrate + Menthol + Ethanol 15mg + 150mg + 60mg + 1mg (100ml)	2000
402	inhaler Fluticasone 125mcg / Puff	1000
403	Inhaler Formeterol Inhaler 12mcg / Dose	2000
404	Inhaler Ipratropium Br + Levosalbutamol 40mcg + 200mcg	6000
405	Syrup Montelukast 5mg / 5ml	2000
406	Tablet Salbutamol 4mg	15000
407	Tablet Salbutamol 2 mg	10000
408	Rotacap levoSalbutamol + Beclometasone rotacaps 50mcg + 50mcg	1500
409	Liquid Salbutamol + Theophylline 20mg + 1000mg (100 ml)	2000
410	Tablet Sustain Release Theophylline 200 mg	30000
411	Tablet Sustain Release Theophylline 400mg	30000
412	Injection Terbutaline 0.5mg 2ml	1200
413	Syrup Terbutaline + Bromhexine 2.5mg + 8mg (100ml)	1700
414	Inhaler MDI Budesonide 400 mcg	2000
415	Syrup Levodropropizine 30mg / 5ml	1200
416	Respule Glycopyrronium 1ml / 25mcg	800
417	DPI (Dry Powder Inhalation) Formoterol + Glycopyrronium 25 + 6mcg	600
418	Tablet Clofazimine 50mg	10000
419	Tablet Clofazimine 100mg	5000
420	Tablet Ethambutol 400mg	1000
421	Tablet INH + Rifampicin + Ethambutol Tab / Combi. Kit of 2 Tabs. 300Mg + 450mg + 800mg	2000

422	Capsule Isoniazid +Rifampicin 300mg+600mg	2500
423	Dispersible Tablet Pyrazinamide 250mg	1000
424	Liquid Pyrazinamide 3gm 60ml	600
425	Capsule Rifampicin 600mg	2800
426	Bottle Rifampicin 100mg / 5ml	250
427	Tablet Rifampicin + Isoniazid + Pyrazinamide (100mg+50mg+300mg)	2000
428	Tablet Rifampicin + Isoniazid + Pyrazinamide (150mg + 100mg + 350mg)	2000
429	Respule Saline(Sodium Chloride) 3%	500
430	Respule Saline(Sodium Chloride) 7%	600
431	Syrup Acetylcysteine 200mg	1640
432	Liquids Diphenhydramine 12.5mg 100ml	500
433	Tablet Pheniramine Maleate 25mg	1200
434	Dextromethorphan Hydrobromide 5 mg Lozenges	50000
435	Cream white soft paraffin and liquid paraffin cream 300 gm	1000
436	Cream Urea + natural moisturizing cream	1500
437	Liquid Liquid Paraffin 400ml – 500ml	1500
438	Injection Zoledronic acid 5mg 100ml	10000
439	Injection Sodium Hyaluronate 20mg / ml	5000
440	Tab. Trypsin / Chymotrypsin 1,00,000AU	40000
441	Lotion Methoxsalen 1%25ml	500
442	Tab. Allopurinol 300mg	10000
443	Lozenges Clotrimazole Lozenges 10mg	1500
444	Lotion Calamine Lotion 8% Calamine (100ml)	1500
445	Injection Hylan Polymer A&B, GF-20 (Intra articular) 48mg	As & when Required
446	Tab. Diacerin 50mg	2000
447	Tab. Thiocolchicoside 4mg	8000
448	Tab. Trypsin + Bromelain + Rutoside (dispersible) 96mg + 180mg + 200mg	10000
449	Oint. Betamethasone + Gentamycin + tolnaftate + iodochlor hydroxy quinone + chlorocresol	1000
450	Infusion flucytosine 2.5gin 250mL	3000
451	I.M Hyaluronic Acid 13mg / ml	6000
452	Capsul eflucytosine 250mg	10000
453	Solid oral dosage for mgriseo fulvin 250mg	6000
454	Cream or lotion Benzyl peroxide 5%	6000
455	Lotion Benzyl Benzoate 25%	4000
456	Cream or ointment Calcipotriol 50 micrograms / mL (0.005%)	4000
457	Lotion Calcipotriol 50 micrograms / mL (0.005%)	2000
458	Ointment Erythromycin 0.005	1000
459	Ointment Fluorouracil 5%.	1000
460	Cream Fusidicacid 0.02	4000

461	Cream or ointment Hydrocortisone 1% (acetate)	1000
462	Lotion Permethrin 1%	4000
463	Ointment Salicylic acid 3-6%	3000
464	Cream Silver Sulfadiazine1%	3000
465	Cream or ointment: Terbinafine 1% (hydrochloride)	1000
466	Eye ointment Tetracycline 1% (hydrochloride)	200
467	Cream or ointment Urea 0.05	30000
468	Cream or ointment Urea 10%	30000
469	Cream Fusidic Acid + Betamethasone 15gm	4000
470	Topical Nano crystalline silver based hydro gel 50g	1000
471	Topical Epidermal growth factor cream 15g	1000
472	Topical Platelet derivedgrowth factor cream 15g	2000
473	Syrup Fluconazole 50mg / 5mL	1000
474	Syrup Itraconazole10mg / mL	1000
475	Powder for oral liquid Voriconazole 40mg / ml	500
476	Ointment Ciprofloxacin 0.30%, 3gm	20232
477	Ointment Betamethasone valerate + Fusidic acid0.12%w/w + 2%w/w (10gm)	2000
478	Ointment Hydroquinone+ Oxybenzone + Octinoxate 2% + 2.5% + 9% (30gm)	2000
479	Ointment Magnesium Sulphate + Urea + Sulfacetamide Sodium	150
480	Tab Methoxsalen10mg	500
481	Ointment Clotrimazole + Betamethasone 1% + 0.05% (20gm)	3690
482	Ointment Sun Screen Lotion SPF 15 + Oxybenzone + Octylmethoxycinnamate 5%+7.5% (75gm)	2000
483	Ointment Tretinoin 0.025% (20gm)	400
484	Topical Solution Ichthammolglycerine10%	2000
485	Inj. Somatogon 60mg PFP	200
486	CapsuleI SOTRETINOIN 10MG	2000
487	CapsuleI SOTRETINOIN 20MG	4000
488	Cream BETAMETHASONE DIPROPIONATE 0.05%	2000
489	Ointment COALTAR + SALICYLIC ACID 3% + 6%	700
490	Gel Sun Screen lotion SPF15 + 100ML	700
491	Ointment Whitesoft Paraffin13.2% (50gm)	3000
492	Tube Zincoxide 8.5% (20gm)	1000
493	Cream Zincoxide + calamine + dimethicone + cetrimide 7.5% + 1.5% + 20% + 1.12%	4000
494	Jelly White Petroleum Jelly 1kg	100
495	Oil Evening primrose oil 500ml	500
496	Lotion Methoxsalen lotion 0.75%	800
497	Ointment Heparin 250IU / gm (20gm)	1500
498	Injection Heparin Lock Flush solution 10 IU / ml vial of 2.0ml	3005
499	Tablet Dapsone 100mg	2500
500	Ointment Tretinoin 0.5% (20gm)	800

501	Pessary Clotrimazole Vag Tablet 100mg	800
502	Tablet Fluconazole 100mg	3530
503	Tablet Flucytosine 500mg	5000
504	Bottle Posaconazole 40mg /150ml	1000
505	Injection Abatacept 250mg	100
506	Cream Hydroquinone + Oxybenzone + Octinoxate 2% + 2.5% + 9% (30gm)	500
507	Ointment Sodium Chloride 6%	61200
508	Syrup Calcium phosphate / carbonate 5ml / 250	800
509	Syrup Calcium phosphate 82mg / 5ml elemental calcium	1000
510	Suspension Vit D 35ml / 60000U	3000
511	Ointment Povidone Iodine 5%W/W (10gm)	1000
512	Injection Orencia 250mg	500
513	Solution Mercurochrome 2%	200
514	Injection Hylan Polymer A & B, GF-20 (Intra articular) 48mg	500
515	Tablet Alendronic Acid 10mg	5000
516	Tablet Alendronic Acid 35 mg	5000
517	Tablet Alendronic Acid + Cholecalciferol 70mg + 5600IU	5000
518	Syrup Calcium Phosphate 80mg / 5ml	150
519	Tablet Colchicine 0.5mg	10000
520	Tablet Colchicine 1mg	10000
521	Cream Sertaconazole 30gm	200
522	Tablet Busulfan 2mg	25000
523	Injection Epirubicin RTU 10mg	5000
524	Injection Epirubicin RTU 50mg	5000
525	Injection Mesna 500mg	50000
526	Intravesical Injection Mitomycin – C 40mg	5000
527	Injection Dacarbazine 100mg	5600
528	Inj. 5 -Fluorouracil 250 mg 5ml	1000
529	Injections Nandrolone Decanoate 50mg 1ml	400
530	Inj. Methotrexate 30mg	1000
531	Powder for injection ifosfamide 500mg	2000
532	Capsul eaprepitant 165mg	20000
533	Solid oral dosage form Chlorambucil 1000 IU / 60000 IU	2000
534	Tablet Dabigatran 50mg	40000
535	Tablet fludarabine 10mg	10000
536	Tablet hydroxycarbamide 200mg	150000
537	Capsule Vancomycin 125mg	30000
538	Suspension Tacrolimus Suspension 0.5 mg / ml	6000
539	Powder for oral suspension in Sachet Aprepitant 125 mg	4000
540	Syrup Diazoxide 50mg / mL	500
541	Injection Taurolidine 2gm / 100ml	500
542	Tablet Afatinib 50mg	450
543	Injection Cisplatin 100mg	300

544	Injection Eribulin 25mg	300
545	Injection Granisetron 3mg 3ml	30000
546	Injection Leucovorin Calcium Folate 3mg 1ml	18000
547	Injection Rasburicase 1.5mg / ml	500
548	Injection Sargramostim 250mg	600
549	Tablet Vandetanib 100mg	1000
550	Intravesical Injection ONCO – BCG 40mg	200
551	Oral Spray Ondansetron hydrochloride 15ml	700
552	Tablet Ponatinib 45mg	400
553	Tablet Olaparib 50mg	500
554	Injection Cyclophosphamide 50mg	2000
555	Inj. Trastuzumab 100mcg	2000
556	Tablet Bosutinib 100mg	500
557	Tablet Bosutinib 400mg	500
558	Tablet Bosutinib 500mg	500
559	Tablet Sorafenib 400mg	1000
560	Injection Aminocaproic Acid 250 mg / ml (20ml)	2500
561	Tablet Apixaban 10mg	1000
562	Topical Solution Hemocoagulase 0.2CU	500
563	Injectable Urokinase 5 lakh units	100
564	Inj. Ramucirumab 500mg/50ml	350
565	Injection Thrombin 1000U	110
566	Injection Leuprolide Acetate 4mg / vial 0.5mg Multidose vial 4ml	500
567	Injection Taurolidine 2gm / 100ml	500
568	Inj. Tislelizumab 100mg	250
569	Injection Methotrexate 15mg	1000
570	Injection Methotrexate 1gm	5000
571	Tablet Methotrexate 10mg	5000
572	Tablet Clopidogrel 300mg	2000
573	Combi pack Artesunate 150 mg + Sulphadoxine - Pyrimethamine (500 mg + 25 mg)	10000
574	Combi pack Artesunate 25 mg + Sulphadoxine – Pyrimethamine (250 mg + 12.5 mg)	8000
575	Tablet amodiaquine 200mg (as hydrochloride)	6000
576	Co-packaged dispersible amodiaquine hydrochloride 76.5 mg + sulfadoxine + pyrimethamine 250 mg + 12.5 mg	20000
577	Co-packaged dispersible amodiaquine hydrochloride 153 mg + sulfadoxine + pyrimethamine 500 mg + 25 mg	As & when Required
578	Oily injection artemether 80mg / m Lin 1m Lampoule.	2000
579	Tablet artesunate + amodiaquine 25mg + 67.5mg	10000
580	Tablet artesunate + amodiaquine 50mg + 135mg	10000
581	Tablet artesunate + mefloquine 25mg + 55mg	10000
582	Tablet artesunate + mefloquine 100mg + 220mg	10000
583	Tablet artesunate + pyronaridine tetraphosphate 60 mg + 180 mg	12000

584	Tablet dihydroartemisinin + piperazine phosphate 20 mg + 160 mg	6000
585	Tablet Mefloquine 250mg	6000
586	Tablet Artesunate Pyrimethamine Sulfadoxine combination 50 mg	10000
587	Granules Artesunate + Pyronaridine Tetraphosphate a 20 mg +60 mg	1000
588	Syrup Trimethoprim 50mg / 5mL	1000
589	Liquid Chloroquin 160mg 10ml	13000
590	Injection Trimethoprim + Sulfamethoxazole 160mg + 800mg 3ml	3000
591	Injection Trimethoprim + Sulfamethoxazole 80 + 400mg	1000
592	Injection Chloroquin 64.5mg 30ml	12400
593	Tablet Arterolane + Piperazine 150mg + 750mg	5000
594	Gel Dinoprostone (3gm) 0.5mg	15000
595	Injection Insulin Glulisine PFS 100 IU / ml (3ml)	15000
596	Syrup Acyclovir 400mg / 5ml	20000
597	Tablet Levonorgestrel + EthinylEstradiol . 15Mg + 0.03mg	2000
598	Injection Gn RH Analogue 4mg / 11.25mg	1000
599	Inj. I. V. Remdesivir	500
600	Inj. Human Isophane Insulinpenfill 100 IU (3ml)	3000
601	Inj. Liraglutide PFS 6mg / ml (3ml)	1500
602	Inj. Mixture of aspart & protamine crystalised penfill 300 IU (3ml)	5000
603	Injections Medroxy progesterone 150 mg (1ml)	1000
604	Inj. Premix rapid acting insulin & intermediate	2000
605	Injection estradiol cypionate + medroxyprogesterone acetate 5 mg + 25 mg	2000
606	Solution for IV infusion zidovudine 10mg / m Lin 20mL vial.	600
607	Injection Insulin Intermediate Acting (NPH) 40IU / mL	10000
608	Tablet Abacavir 60mg	6000
609	Tablet Abacavir 300mg	6000
610	Tablet Abacavir 60mg + Lamivudine 30mg	6000
611	Tablet Darunavir 50mg	10000
612	Tablet Darunavir 0.5mg + Ritonavir 2mg	10000
613	Tablet Dinoprostone 0.5mg	40000
614	Tablet dasabuvir 250mg	20000
615	Tablet diazoxide 50mg	40000
616	Tablet Efavirenz 200mg	10000
617	Tablet efavirenz + lamivudine + tenofovir 400 mg + 300 mg + 300 mg	10000
618	Tablet ethinylestradiol + norethisterone 35micrograms + 1mg	10000
619	Capsule/Sachet (containing pellets / granules) Lopinavir 40mg + Ritonavir 10mg	10000
620	Tablet Lopinavir 100mg + Ritonavir 25mg	10000
621	Tablet Lopinavir 100mg + Ritonavir 25mg	10000
622	Dispersible Tablet Nevirapine 50mg	10000
623	Tablet Raltegravir 400mg	10000

624	Tablet Tenofovir Disproxil Fumarate 300 mg + Lamivudine 300 mg	20000
625	Tablet Zidovudine 300mg	10000
626	Tablet Zidovudine 60mg + Lamivudine 30mg	10000
627	Tablet Zidovudine 60 mg + Lamivudine 30 mg + Nevirapine 50 mg	10000
628	Syrup Entecavir 0.05mg / mL	500
629	Granules Glecaprevir + Pibrentasvir 50mg + 20mg in sachet	500
630	Syrup Griseofulvin 125mg / 5mL	500
631	Syrup Lamivudine 50mg / 5mL	500
632	Syrup Lopinavir 80mg + Ritonavir 20mg	2000
633	Syrup Nevirapine 50mg / 5mL	500
634	Granules for oral suspension Raltegravir 100mg in sachet	500
635	Powder for oral solution Valganciclovir 50mg / mL	As & when Required
636	Syrup Zidovudine 50mg / 5ml	500
637	Injection Human Biphasic Isophane Insulin 25 / 75 penfill 300IU (3ml)	4000
638	Injection Peginterferon Alpha – 2b80mcg 0.5ml	180
639	Inj. Pertuzumab + Transtuzumab 1200mg +600mg	100
640	Tablet Ribavirin 200mg	1000
641	Injection Remdesivir 100mg	700
642	Tablet Nitazoxanide 500mg	700
643	Tablet Valacyclovir 1gm	2000
644	Injection Prostaglandin150mcg 1mlamp	500
645	Cream Conjugated equine estrogen cream	1000
646	Injection ACTH 250mcg	900
647	Gel Testosterone 1%w/w	50
648	Tablet Ethinylestradiol 0.05	5000
649	Injections Desmopressin 4mcg	600
650	Injection Dulaglutide 0.75mg / 0.5ml	500
651	Tablet Ethinylestradiol 0.01mg	5000
652	Inj. Dostarlimab GXL 500mg	200
653	Tablet Gemigliptine 50mg	5000
654	Injections Medroxy progesterone 150mg (1ml)	500
655	Tablet Medroxy progesterone 10mg	5000
656	Tablet Misoprostol 400mcg	500
657	Tablet Misoprostol (Prostaglandine E1) 50mcg	5000
658	Injections Nandrolone Decanoate 25mg 1ml	100
659	Injections Nandrolone Phenl Propionate 25mg	500
660	Injections Nandrolone Phenyl Propionate 50mg	500
661	Injection Progesterone 200mg	500
662	Injection Micronosed Progesterone 100mg 1ml	500
663	Injection Norethisterone 200mg 1ml	2000
664	Injection Insulindetemir Flexpen 3ml	5000
665	Inj. Iomeprol 350mg / ml (100ml)	1000

666	Inj. Iomeprol 400mg / ml (50ml)	500
667	Solution Povidone Iodine 5% 100ml	1000
668	Solution Povidone Iodine 5% 500ml	1000
669	Injection Haemodialysis fluid As licensed	10000
670	I.V Sulfur Hexa fluoride 2.8ml	1000
671	Oral Liquid Barium sulphate 95%w/v	1000
672	Injection Gadobenatedimeglumine 334mg +195mg / ml (10ml)	500
673	Two Port Close system container Ciprofloxacin 100ml	4000
674	Injection Dimeglumine gadobenate 20ml	500
675	Injection Fluoscindye 600mg	100
676	Injection Iobitridol 300mg 100ml	1000
677	Injection Iobitridol 350mg 50ml	1000
678	Injection Iobitridol 300mg 50ml	1000
679	Injection Iomeprol 300mg / ml (50ml)	500
680	Injection Iomeprol 350mg / ml (50ml)	500
681	Injection Iomeprol 400mg / ml (75ml)	500
682	Injection Ioversol 300mg / ml (50ml)	1000
683	Injection Ioversol 300mg / ml (100ml)	1000
684	Injection Ioversol350mg /ml (50ml)	1000
685	Injection Ioversol 350mg /mg (100ml)	1000
686	Injection Ioxaglate 320mg / ml (50ml)	1000
687	Injection Ioxaglate 320mg / ml (100ml)	1000
688	Injection Megluminediatrizoate 0.65mg / ml (10ml)	1100
689	Injection Iobitridol 300mg / 100ml	1000
690	Injection Bicarb fluid with high Concentration of sodium (103mgdl)	2000
691	Two Port Closesystem container Dextrose10% 500ml	850
692	I.V. bag Dextrose (self collapsible bag without requiring any airway) 10% 500 ml	11000
693	Plastic Dextrose (FFS) 20% 500ml	100000
694	I.V. bag Dextrose (self collapsible bag without requiring any airway) 20% 500 ml	11000
695	I.V. bag Mannitol (self collapsible bag without requiring any airway) 20% 500ml	4000
696	I.V. bag Mannitol (self collapsible bag without requiring any airway) 20% 100 ml	4000
697	Glass Dextrose 20% 500ml	38000
698	Fluid PD Fluid 4.25% dextrose 2 Litre	4000
699	Plastic Distilled water (PlasticCan) 5Litre	10000
700	Injection Balance Salt solution (Sodium Chloride + Potassium Chloride + Calcium Chloride + Magnesium Chloride + Sodium Acetate + Sodium Citrate) 500ml (6.4mg + 0.75mg + 0.48mg + 0.3mg + 3.9mg +1.7mg/ml)	600
701	Liquid Hydrogen Peroxide1ltr.	2605
702	Liquid Tincture Benzoin 400ml – 500ml	2000

703	Liquid Tincture Iodine 400ml – 500ml	2000
704	Liquid Formaldehyde 5Ltr.	100
705	Liquid Glycerin 1000gm	1200
706	Solution Povidone Iodine 5% 100ml	1500
707	Solution Povidone Iodine 5% 500ml	1000
708	Injection Water for Injection 5ml	33195
709	Collapsible bag Sterile water	2000
710	Injection Iomeprol 300mg / ml (100ml)	400
711	Liquid Thymol + Eucalyptol 0.09% + Benzoic acid + Menthol + Ethyl Alcohol 0.06% + 0.09% + 0.15% + 0.04% + 26%v/v (85ml)	10000
712	Tablet Mirabegron 25mg 25mg	100000
713	Injection Palonosetron 0.5mg	50000
714	Tablet Midostaurin 25mg	50000
715	Injection Triamcinolone Acetonide 40mg 1ml	50000
716	Nasal Drop Xylometazoline Nasal Drop (Peads) 0.0005	25000
717	Tab. Penicillamine 250mg	10000
718	Tab Tacrolimus 5mg	5000
719	Tab. Allopurinol 100mg	15000
720	Tab. Ibandronate 150mg	10000
721	Injection ergometrine 200 micrograms (hydrogen maleate) in 1 mL ampoule.	1000
722	I. M normal immunoglobulin 16% protein solution	4000
723	S. C normal immunoglobulin 15% protein solution	8000
724	S. C normal immunoglobulin 16% protein solution	4000
725	Injection pyridostigmine 1 mg in 1 mL ampoule.	600
726	Injection sodium calcium edetate 200mg / mL in 5 mL ampoule.	6000
727	Injectable solution sodium hydrogen carbonate 1.4% isotonic (equivalent to Na + 167 mmol / L, HCO ₃ -167mmol / L)	500
728	Injectable solution sodium hydrogen carbonate 8.4% in 10 mL ampoule (equivalent to Na + 1000mmol / L, HCO ₃ -1000mmol / L)	500
729	Powder for injection suramin sodium 1g in vial	500
730	Injection suxamethonium 50mg / mL (chloride) in 2 mL ampoule.	550
731	Powder for injection : (chloride) , in vial.	As & when Required
732	Injection tacrolimus 5 mg / mL in 1mL vial.	500
733	Injection testosterone 200 mg (enanthate) in 1 mL ampoule.	1000
734	Injection Prednisolone 20mg / 2mL	6000
735	Inj. Sodium tetradecyl Sulfate (2ml vial)	1000
736	Tablet benznidazole 12.5mg	20000
737	Tablet benznidazole 100mg	15000
738	Tablet Clomiphene citrate 0.5 mg	6000
739	Tablet D-Penicillamine 30mg	20000
740	Tablet Dexamethasone 50mg	100000

741	Tablet fexinidazole 600mg	6000
742	Capsule iodine 190mg	2000
743	Tablet Methylergometrine 0.125mg	20000
744	Tablet Neostigmine 15mg	20000
745	Tablet Dexamethasone 0.5mg	40000
746	Tablet ARMODAFINIL 100MG	10000
747	Oral Polyethylene Glycol Powder (adults)135mg	30000
748	Powder Activated Charcoal	40000
749	Retention enema prednisolone20 mg / 100 mL (as sodium phosphate)	10000
750	Topical Silver based spray 60ml	4000
751	Inhalation Nitrous Oxide	100
752	Inhalation (medicalgas) Oxygen	100
753	Topical Acetic Acid 2% , inalcohol	2000
754	Topical Glycerin / glycerol I.P	10000
755	Topical Methylrosanilinium chloride (Gentian Violet) 0.25% to 2%	2000
756	Syrup Dexamethasone 0.5mg / 5ml	500
757	Syrup Ergocalciferol 250 micrograms / mL (10 000 IU / mL)	500
758	Oral Liquid Lugol's solution 130 mg total iodine / mL	2000
759	Syrup Oxamniquine 250mg / 5mL	500
760	Granules p – amino salicylic acid 4g in sachet	500
761	Jelly Glycerine + hydroxyethyl cellulose	500
762	Tablet Levocarnitine 500mg	10000
763	Inhaler Ciclesonide 160mcg	600
764	Tablet Deflazacort 18mg	10000
765	Solution Dornase alpha Inhalation Solution 1000 U (1mg) / 1ml	500
766	Injection Succinylatedgelatins 4% 500ml	500
767	Injection Polidoconal 3% 2ml	150
768	Powder POTASSIUM PERMANGANATE 400MG	500
769	Injection Desferrioxamine 500mg	1000
770	Tablet Prednisolone 40mg	238668
771	Tablet Phenazopyridine 200mg	5000
772	Tablet Acetylsalicylic acid + calcium Carbonate + Anhydrous citric acid 325mg + 100mg + 35mg	5000
773	Tablet POTASSIUM PERMANGANATE 400MG	1000
774	Ointment Magnesium Sulphate	500
775	Sachet Sodium Phosphate	500
776	Mouth Wash Alcohol Free Benzydamine 0.15% 500 ml	300
777	Liquid Chloramphenicol + Clotrimazole + Beclometasone Dipropionate + Lignocaine HCL ear drop 5% + 1% + 0.25% + 2% (5ml)	500
778	Mouth Wash Chlorxylenol + Menthol + Alcohol (Denatured) Mouthwash & Gargle.1.02% + 0.12% + 60.8% (500ml)	500

779	Capsule Combination of Eucalyptol , Methol , Terpeneol Camphor , Chlorothymol etc. for Inhalation	7060
780	Paste Medicated Toothpaste containing + trontium Chloride , Potassium Nitrate + , Formaline etc. 10% + 5% (50gm)	9555
781	Ear Drop Wax Softener E / D (Paradichloro benzene + benzocaine + chlorbutol + turpentine oil) 10ml	500
782	Solution Carbolic Acid 400gm – 500gm	14400
783	Enema Phosphate Enema 100ml	14190
784	Intracavernosal Injection ALPROSTADIL (PGEI) 20mcg	500
785	Suppository Glycerine 1.2gm	500
786	Enema Glycerin and sodium chloride enema 20ml	500
787	Suspension Cotrimoxazole (Trimethoprim + Sulphamethoxazole) 80mg + 200mg	800
788	IM Intra-articular METHYL PREDNISOLONE ACETATE 40MG + 80MG	500
789	Scrub Povidone iodine + Chlorhexidine scrub	1000
790	Solution Chlorinated lime with Boric Acid solution	1000
791	Ointment Magnesium Sulphate + Urea + Sulfacetamide Sodium	600
792	Sachet Polyethylene glycol (pediatric preparation) 6.85gm	600
793	Injection Methylene blue 10mg / ml	500
794	Syrup Potassium citrate 1100mg / ml	1000
795	Syrup ursodeoxy cholic acid 125mg / 5ml	44105
796	Powder Prussian Blue (Insoluble) 50gm	300
797	Powder Prussian Blue (Insoluble) 100gm	200
798	Oral Sachet Polyethylene Glycol Sachet 117gm	5000
799	Gel Benzocaine Gel 0.2	400
800	Tablet Iron Pyrophosphate Liposomal 30mg	500
801	Injection Chromium Chloride + Copper Sulphate + Manganese Sulphate + Selenious Acid 3ml	350
802	Syrup Levo – Carnitine 500mg / 5ml	500
803	Syrup Iodised Peptone , Manganese Chloride 300ml	500
804	Syrup Iodised Peptone , Manganese Chloride 300ml	2000
805	ointment Benzyl Nicotinate + Heparin Sodium 2mg + 50 IU	500
806	Syrup Iodised Peptone + Magnesium Chloride + Magnesium Sulphate + Sodium Metavandate + Zinc Sulphate + Pyridoxine + Cyanocobalamin + Nicotinamide + Ethanol 0.32mg + 6.67mg + 1.33mg + 0.22mg + 10.71mg + 0.25mg + 0.16mg 3.33mg + 0.317ml	500
807	Capsule Chlorothymol + Menthol + Terpin + Camphor + Eucalyptus Globulus 5.0 mg + 55 mg + 120mg + 25mg + 125mg	2500
808	Sachet Bioactive Collagen Peptide (Food Grade) 10.2gm	1000

809	Face wash Glycolic acid + Salicyclic acid Witch Hazel Extract + Aloe vera + Vitamin E 100ml	500
810	Face wash Vitamin EAcetate + GlycolicAcid + Aloe Vera 100gm	500
811	Lotion LacticAcid (1.2%) , Sorbitol (1%) , Cocamidopropyl Betaine (7%) , Polyquaternium (70.5%) , Melaleuca Alternifolia (0.05%) , Hippophae Rhamnoides (0.25%) 100ml	1000
812	Gel Pegylated Hydrogel 6 x 6cm	800
813	Oral Solution Surcose 0.24	400
814	Tablet Voxelotor 500mg	2000
815	Gel Sod . Fluoride 1.1% (100gm)	4000
816	Syrup Prednisolone 15mg / 5ml	800
817	Tablet Methimazole 10mg	5000
818	Tablet Tizanidine 2mg	5000
819	Tablet Allopurinol SR 100mg	5000
820	Tablet Cinacalcet 60mg	5000
821	Tablet Cabergoline 0.5mg	5000
822	Injection Crizanlizumab10mg / ml	5000
823	Lactose Sugar & Gluten Free Probiotic	10000
824	Tablet containing Amino Acids , Vitamins , Minerals , Biotin , Melatonin and Botanical Extracts	50000
825	Injection Arsenic trioxide 1mg / mL	2000
826	BCG vaccine	3000
827	Injection Betamethasone 4mg / mL	2000
828	Capsule D-Penicillamine 150mg	5000
829	Capsule D-Penicillamine 250mg	5000
830	Diphtheria antitoxin	2000
831	DPT vaccine	2000
832	Fluorescein Ophthalmic Strips	1000
833	Glutaraldehyde solution	1000
834	Hepatitis B immunoglobulin 540IU / 3ml	2500
835	Hepatitis B immunoglobulin 180IU / ml	2500
836	Homatropine Drops 2%	3000
837	Inj. Hydroxypropyl methylcellulose 2%	3000
838	Powder for Injection Ifosfamide 1000mg	2000
839	Granules / Husk / Powder Ispaghula	5000
840	Tab. Levonorgestrel 0.75mg	5000
841	Tab. Levothyroxine 50mcg	5000
842	Measles vaccine	1000
843	Oral poliomyelitis vaccine	2000
844	Oral rehydration salts	5000
845	Rotavirus vaccine	1000
846	Injection Sodium thiosulphate 250mg / ml	2000
847	Powder for Injection Streptomycin 750mg	2000
848	Drops Travaprost 0.04%	3000